 |
| | | | News Releases |
|
| Date | Title | | | 11/18/09 | St. Jude Medical To Present at the 21st Annual Piper Jaffray Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 18, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will present at the 21st Annual Piper
Jaffray Health Care Conference on Tuesday, December 1, in New York City.
John C. Heinmiller, executive vice president and chief financial
officer, will address the conference at 10:00 a.m. ET. The presentation
will also be Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops med... |
|  | | 11/18/09 | 62-Year-Old Man Becomes First Patient in China Implanted with Rechargeable Neurostimulator for Chronic Pain|
St. Jude Medical receives Chinese State Food and Drug Administration
approval for Eon and Genesis neurostimulators for chronic pain
ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 18, 2009--
St. Jude Medical, Inc. (NYSE:STJ) announced today that a 62-year-old man
from Shenzhen, Guangdong province has become the first patient in China
to be implanted with the Eon™ neurostimulator, a rechargeable
device used to help manage chronic pain. Despite ... |
| | | 10/30/09 | St. Jude Medical To Present at the 2009 Credit Suisse Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 30, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will present at the 2009 Credit Suisse
Healthcare Conference on Thursday, November 12, in Phoenix. Eric S.
Fain, M.D., president of the St. Jude Medical Cardiac Rhythm Management
Division, will address the conference at 2:00 p.m. MST. The presentation
will also be Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops... |
| | | 10/23/09 | St. Jude Medical Board of Directors Authorizes Share Repurchase| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 23, 2009--
St. Jude Medical, Inc. (NYSE:STJ) announced today that its Board of
Directors has authorized a share repurchase of up to $500 million of its
outstanding common stock. The repurchases will occur at such times and
at such prices as the management of the Company determines and may be
effected through transactions in the open market, in privately
negotiated transactions or otherwise.
Comm... |
| | | 10/21/09 | St. Jude Medical Reports Third Quarter 2009 Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 21, 2009--
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings
for the third quarter ended October 3, 2009.
Third Quarter Sales
The Company reported net sales of $1.160 billion in the third quarter of
2009, an increase of 7 percent compared with the $1.084 billion in the
third quarter of 2008. Foreign currency translation comparisons
decreased third quarter sales b... |
| | | 10/20/09 | St. Jude Medical Announces European CE Mark Approval and First Implant of Industry's First Quadripolar Pacing System|
System offers physicians additional pacing options and more flexibility
in selecting pacing configurations during and after implant procedures
ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 20, 2009--
St. Jude Medical, Inc. (NYSE: STJ) today announced it has received
European CE Mark approval for the industry’s first quadripolar pacing
system for cardiac resynchronization therapy defibrillators (CRT-Ds).
The quadripolar system offers physicia... |
| | | 10/06/09 | St. Jude Medical Announces Preliminary Third Quarter Results| ST. PAUL, Minn., Oct 06, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced preliminary results
for the third quarter ended October 3, 2009.
Preliminary Third Quarter Results
The Company expects to report net sales of approximately $1.159 billion
in the third quarter of 2009, an increase of 7 percent compared to the
third quarter of 2008. Foreign currency translation comparisons
decreased third quarter sales by approximately $29 million. ... |
| | | 09/23/09 | FAME Trial Two-Year Follow-Up Results Demonstrate Continued Reduction in Risk of Death or Heart Attack When Physicians Use St. Jude Medical Fractional Flow Reserve Technology Prior to Implanting Coronary Stents|
Trial Demonstrates an FFR-Guided Strategy to Treat Multivessel Coronary
Artery Disease Both Improves Outcomes and is Cost-Saving Compared to
Procedures Using Angiography Alone
ST. PAUL, Minn.--(BUSINESS WIRE)--Sep. 23, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced that the two-year
results from the landmark FAME (Fractional
Flow Reserve (FFR) vs. Angiography
in Multivessel Evaluation)
trial demonstrated the durabili... |
| | | 09/22/09 | St. Jude Medical to Showcase Complete Cardiovascular Access, Intervention and Hemostasis Management Solutions at Transcatheter Cardiovascular Therapeutics (TCT) 2009| ST. PAUL, Minn., Sep 22, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced it will display
products and technologies from the company's portfolio of solutions for
cardiovascular healthcare professionals at the 21st annual Transcatheter
Cardiovascular Therapeutics meeting in San Francisco. The featured
products reflect the company's continued commitment to developing
comprehensive, high-performance solutions which advance the practic... |
| | | 09/21/09 | Blood Flow Blockages in the Heart Can Now Be Measured Using St. Jude Medical Wireless Fractional Flow Reserve Technology|
New diagnostic tool combines St. Jude Medical’s PressureWire Aeris with
GE’s Mac-Lab Hemodynamic Recording System to provide physicians with a
wireless solution to aid the diagnosis and treatment of coronary artery
blockages
ST. PAUL, Minn.--(BUSINESS WIRE)--Sep. 21, 2009--
St. Jude Medical, Inc. (NYSE: STJ) today announced the first use of the
PressureWire™ Aeris technology, an interventional tool which measures
Fractional Flow Reserv... |
| | | 09/14/09 | St. Jude Medical Announces FDA Approval of EnSite Velocity Cardiac Mapping System| Next-generation cardiac mapping system gives physicians the ability to increase procedural efficiency and speed for treating irregular heart rhythms ST. PAUL, Minn., Sep 14, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) today announced U.S. Food and Drug
Administration (FDA) clearance and U.S. launch of its EnSite
Velocity(TM) Cardiac Mapping System. This new system has been designed
to help physicians more efficiently diagnose and guide therapy to treat ... |
| | | 09/09/09 | St. Jude Medical to Present at the Morgan Stanley Global Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Sep. 9, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will present at the Morgan Stanley
Global Healthcare Conference on Tuesday, September 15, in New York City.
Daniel J. Starks, chairman, president and chief executive officer, will
address the conference at 8:35 a.m. ET. The presentation will also be
Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops medical technol... |
| | | 09/09/09 | St. Jude Medical Receives CE Mark Approval for World's Smallest, Longest-Lasting Rechargeable Deep Brain Stimulator for Parkinson's Disease|
First patient implanted with Brio neurostimulator at University of
Cologne, Germany
ST. PAUL, Minn.--(BUSINESS WIRE)--Sep. 9, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced CE (Conformité
Européenne) Mark approval of the Brio™ neurostimulator,
the world’s smallest, longest-lasting rechargeable deep brain
stimulation (DBS) device for treating the symptoms of Parkinson’s
disease. A 67-year-old man who has su... |
| | | 08/31/09 | St. Jude Medical Announces European Launch of New Version of Remote Patient Care Network|
Version 4.0 of Merlin.net Patient Care Network (PCN) represents
important next step in health care connectivity
ST.PAUL, Minn.--(BUSINESS WIRE)--Aug. 31, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced European launch of the
next generation Merlin.net™
Patient Care Network (PCN), a secure, Internet-based remote care system
for patients with implanted medical devices.
Merlin.net PCN gathers and stores data fro... |
| | | 08/28/09 | St. Jude Medical Announces Opening of European Advanced Learning Center For Continuing Physician Education in Heart Disease Therapies|
EBAC-accredited interventional EP curriculum is among offerings of the
Brussels center
ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 28, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced the official opening
of the St. Jude Medical Advanced Learning Center, in Brussels, Belgium,
offering education and training in advanced, evidence-based therapies
for physicians who treat heart disease.
The center’s curricula include ... |
| | | 08/26/09 | St. Jude Medical To Present at the Thomas Weisel Partners Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 26, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will present at the Thomas Weisel
Partners Healthcare Conference on Thursday, September 10, in Boston.
John C. Heinmiller, executive vice president and chief financial
officer, will address the conference at 3:50 p.m. ET. The presentation
will also be Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops medical tech... |
| | | 07/23/09 | St. Jude Medical, Inc. Announces Pricing of Public Offering of Senior Debt| ST. PAUL, Minn.--(BUSINESS WIRE)--Jul. 23, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced that it has priced an
offering to sell $700 million of senior notes due 2014 (the "2014
Notes") and $500 million of senior notes due 2019 (the "2019 Notes").
The 2014 Notes will bear interest at 3.750% per year and, unless
previously redeemed, will mature on July 15, 2014. The 2019 Notes will
bear interest at 4.875% per year and, unless previously rede... |
| | | 07/23/09 | St. Jude Medical Announces Commencement of Public Offering of Senior Debt| ST. PAUL, Minn.--(BUSINESS WIRE)--Jul. 23, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced it is commencing an
offering of senior debt securities, subject to market and other
customary conditions. The Company intends to use the net proceeds from
the offering for general corporate purposes, which may include the
repayment of certain of its indebtedness and the repurchase of its
outstanding common stock pursuant to its authorized $500 million ... |
| | | 07/22/09 | St. Jude Medical Reports Second Quarter 2009 Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Jul. 22, 2009--
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings
for the second quarter ended July 4, 2009. The Company also announced
today that its Board of Directors has authorized the repurchase of up to
$500 million of St. Jude Medical common stock.
Second Quarter Results
The Company reported net sales of $1.184 billion in the second quarter
of 2009, an increase... |
| | | 07/21/09 | St. Jude Medical Announces Completion of European Enrollment in its Trifecta Stented Tissue Valve Trial| ST. PAUL, Minn.--(BUSINESS WIRE)--Jul. 21, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced that it has completed
enrollment in its European clinical trial to evaluate Trifecta™, a
stented pericardial tissue heart valve.
The Trifecta clinical trial is a multi-center, prospective study, which
enrolled 120 patients at six centers throughout Europe. The trial will
evaluate the safety and efficacy of the Trifecta stented tissue va... |
| | | 07/21/09 | St. Jude Medical Announces FDA Approval of Accent RF and Anthem RF Pacemakers Equipped With Wireless Technology| ST. PAUL, Minn.--(BUSINESS WIRE)--Jul. 21, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of its Accent™
RF pacemaker and Anthem™
RF CRT-P (cardiac resynchronization therapy pacemaker). The company
also announced FDA and European CE Mark approval of version 4.0 of the Merlin.net®
Patient Care Network (PCN), which supports the Accent RF and Anthem
RF devices.
... |
| | | 07/14/09 | St. Jude Medical Announces Australian TGA Regulatory Approval for Libra Deep Brain Stimulation Systems for Parkinson's Disease| ST. PAUL, Minn.--(BUSINESS WIRE)--Jul. 14, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced Australian Therapeutic
Goods Administration (TGA) approval of its Libra® and LibraXP™
deep brain stimulation (DBS) systems for treating the symptoms of
Parkinson’s disease, a neurological disorder that progressively
diminishes a person’s control over his or her movements.
Similar to a heart pacemaker, the Libra DBS systems f... |
| | | 07/08/09 | St. Jude Medical Announces Second Quarter 2009 Earnings Conference Call| ST. PAUL, Minn.--(BUSINESS WIRE)--Jul. 8, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will hold its quarterly conference
call to discuss Second Quarter 2009 results on Wednesday, July 22, at
8:00 a.m. Eastern Time (7:00 a.m. Central Time). A news release will be
issued at 7:30 a.m. Eastern Time (6:30 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical’s web site at www.sjm.com.
... |
| | | 06/23/09 | St. Jude Medical Applauds MADIT-CRT Trial| ST. PAUL, Minn.--(BUSINESS WIRE)--Jun. 23, 2009--
St. Jude Medical, Inc. (NYSE: STJ) today commends the efforts of
investigators in the Multicenter Automatic Defibrillator Implantation
Trial with Cardiac Resynchronization Therapy (MADIT-CRT). The early
results of the trial indicate that early intervention with CRT-D therapy
can slow a patient’s progression from early stage heart failure (NYHA
Class I-II) to late stage heart failure (NYHA Class ... |
| | | 06/17/09 | St. Jude Medical Announces FDA Approval of the Cool Point Irrigation Pump| Automated irrigation pump provides control over fluid delivery during radiofrequency (RF) catheter ablation procedures
ST. PAUL, Minn.--(BUSINESS WIRE)--Jun. 17, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of its Cool Point™ Irrigation Pump. Used
in conjunction with SJM open-irrigated ablation catheters, an irrigation
pump supplies a continuous flow of saline through the catheter’s inner
lumen t... |
| | | 06/12/09 | St. Jude Medical Announces Leading Sponsorship of Landmark Clinical Trial to Study Atrial Fibrillation| ST. PAUL, Minn.--(BUSINESS WIRE)--Jun. 12, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced that it is the leading
sponsor of the Catheter Ablation Versus Anti-arrhythmic Drug Therapy for
Atrial Fibrillation (CABANA) Trial. The pivotal trial, announced today
by Mayo Clinic, is intended to determine the effectiveness of catheter
ablation (using long, narrow tubes to non-invasively reach and destroy
abnormal heart tissue) in eliminating atrial ... |
| | | 06/10/09 | St. Jude Medical Announces Initial Implant of First-to-Market Connector System in the U.S.| New Streamlined Design Expected to Offer Implanting Physicians a More Efficient Procedure and Improve Patient Comfort ST. PAUL, Minn., Jun 10, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced the first implant of
its Current(R) Plus implantable cardioverter defibrillator (ICD),
featuring the SJ4 connector system. The St. Jude Medical SJ4 connector
reduces the number of connections between the device and the wires
(defibrillation leads)... |
| | | 06/08/09 | St. Jude Medical Acquires Intellectual Property and Non-Cash Assets of Northstar Neuroscience, Inc.| Acquisition strengthens St. Jude Medical's neuromodulation intellectual property portfolio ST. PAUL, Minn., Jun 08, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ), announced today the acquisition of
the intellectual property and non-cash assets of Northstar Neuroscience,
Inc. (Nasdaq:NSTR), a medical device company, for a payment of $2
million.
"Today's announcement reflects St. Jude Medical's strong commitment to
developing our neuromodulation bus... |
| | | 06/08/09 | St. Jude Medical Completes Implants in U.S. Study of Deep Brain Stimulation for Parkinson's Disease| ST. PAUL, Minn.--(BUSINESS WIRE)--Jun. 8, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced the completion of
patient implants in its U.S. pivotal clinical study of deep brain
stimulation (DBS) for the symptomatic treatment of Parkinson’s disease,
a neurological disorder affecting approximately 6.3 million people
worldwide that progressively diminishes a person’s control over his or
her movements. The announcement was made at the M... |
| | | 05/26/09 | St. Jude Medical To Present at the William Blair & Company's 29th Annual Growth Stock Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 26, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will present at the William Blair &
Company's 29th Annual Growth Stock Conference on Thursday, June 11, in
Chicago. John C. Heinmiller, executive vice president and chief
financial officer, will address the conference at 11:20 a.m. CDT. The
presentation will also be Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops m... |
| | | 05/18/09 | Patients in St. Jude Medical Deep Brain Stimulation for Depression Pilot Study Demonstrate Sustained Improvement in Depression Symptoms| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 18, 2009--
According to the latest data in a clinical study supported by St. Jude
Medical, Inc. (NYSE:STJ), deep brain stimulation (DBS) therapy for
depression may provide sustainable improvement in depression symptoms
among patients with major depressive disorder. Study results will be
presented today at the American Psychiatric Association (APA) meeting in
San Francisco.
This study profiles 21... |
| | | 05/14/09 | St. Jude Medical Announces Results From STAR-AF Trial| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 14, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced the results from the Substrate
versus Trigger Ablation
for Reduction of Atrial
Fibrillation (STAR-AF) trial. The
findings were presented today during a late-breaking clinical trials
session at Heart Rhythm 2009, the annual Heart Rhythm Society’s
Scientific Sessions in Boston.
The STAR-AF trial, sponsored by St. Jude Medica... |
| | | 05/13/09 | St. Jude Medical to Highlight Comprehensive Arrhythmia Management Solutions and Electronic Health Record Connectivity at Heart Rhythm 2009| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 13, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced it will display a
number of new products and technologies at the annual Heart
Rhythm Society meeting in Boston this week, highlighting the
company’s commitment to providing the most comprehensive and
technologically advanced portfolio of therapies and devices for the
treatment of heart arrhythmias, including products enabled with wireless
... |
| | | 05/13/09 | St. Jude Medical Announces European Approval of Accent RF and Anthem RF Pacemakers Equipped With Wireless Technology| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 13, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its Accent™
RF pacemaker and Anthem™
RF CRT-P (cardiac resynchronization therapy pacemaker).
The Accent and Anthem product family features RF
telemetry that enables secure, wireless communication between the
implanted device and the programmer used by the clinician, making it the
first in... |
| | | 05/12/09 | St. Jude Medical Announces European CE Mark Approval and First Use of Next-Generation Cardiac Mapping System| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 12, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval and first use of its EnSite Velocity™ Cardiac Mapping System.
This new system has been designed to help physicians more efficiently
diagnose and deliver therapy to treat abnormal heart rhythms. St. Jude
Medical will feature the EnSite Velocity System in booth #603 at the
annual Heart Rhythm Society (HRS) Scientific Sessi... |
| | | 05/11/09 | St. Jude Medical Announces European Approval of Its Newest Heart Failure Devices Which Enable More Efficient Implantation and Follow-up| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 11, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its Promote Accel™ implantable cardiac resynchronization
therapy defibrillator (CRT-D). The Promote Accel CRT-D automatically
tailors treatment to individual patient needs by measuring the heart’s
reaction to therapy and ensuring that the heart is responding, providing
the dual benefit of added safety for the pa... |
| | | 05/11/09 | CORRECTING and REPLACING St. Jude Medical Announces FDA Approval of Current Plus ICD and Promote Plus CRT-D Devices to Provide Therapy for Life-Threatening Arrhythmias and Heart Failure| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 11, 2009--
Please replace the release with the following corrected version due to
publication of incorrect Forward-Looking Statements.
The corrected release reads:
ST. JUDE MEDICAL ANNOUNCES FDA APPROVAL OF CURRENT PLUS ICD AND
PROMOTE PLUS CRT-D DEVICES TO PROVIDE THERAPY FOR LIFE-THREATENING
ARRHYTHMIAS AND HEART FAILURE
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S... |
| | | 05/11/09 | St. Jude Medical Announces FDA Approval of Current Plus ICD and Promote Plus CRT-D Devices to Provide Therapy for Life-Threatening Arrhythmias and Heart Failure| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 11, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of the Promote® Plus cardiac
resynchronization therapy defibrillator (CRT-D) and Current® Plus
implantable cardioverter defibrillators (ICDs), designed with TailoredTherapy™
features that give physicians more options for customizing therapy for
patients with potentially lethal heart arrhythmias and... |
| | | 05/08/09 | St. Jude Medical Announces Results of Shareholders' Vote at Annual Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 8, 2009--
St. Jude Medical, Inc. (NYSE:STJ) announced at its annual meeting of
shareholders today that John W. Brown and Daniel J. Starks were
re-elected to the Company's Board of Directors for three-year terms.
In addition, shareholders approved the St. Jude Medical, Inc. Management
Incentive Compensation Plan and ratified the appointment of Ernst &
Young LLP as the Company's Independent Registere... |
| | | 05/06/09 | St. Jude Medical Announces FDA Clearance and Launch of the Attune Annuloplasty Ring for Heart Valve Repair| ST. PAUL, Minn.--(BUSINESS WIRE)--May. 6, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced the U.S. launch of its
Attune™ Flexible Adjustable Annuloplasty Ring for the repair
of diseased heart valves. The company received U.S. Food and Drug
Administration clearance and will introduce the product at the annual
meeting of the American Association for Thoracic Surgery in Boston, on
May 9.
The mitral valve controls the flow... |
| | | 04/29/09 | St. Jude Medical to Present at Banc of America Securities Merrill Lynch 2009 Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 29, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will present at the Banc of America
Securities Merrill Lynch 2009 Health Care Conference on Tuesday, May 12,
in New York City. Daniel J. Starks, chairman, president and chief
executive officer, will address the conference at 8 a.m. EDT. The
presentation will also be Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develo... |
| | | 04/24/09 | St. Jude Medical Announces CE Mark Approval of Remote Care System for Implantable Cardiac Devices| Cutting-edge Web-based system, Merlin.net Patient Care Network (PCN), combines tools that can help physicians monitor patients and improve clinic efficiency
ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 24, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its Merlin.net™ Patient Care Network (PCN). Merlin.net PCN
is a secure, Internet-based remote care system that gathers and stores
data from the implant procedure, a clinic follow-up... |
| | | 04/22/09 | St. Jude Medical Reports First Quarter 2009 Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 22, 2009--
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings
for the first quarter ended April 4, 2009.
First Quarter Sales
The Company reported net sales of $1.134 billion in the first quarter of
2009, an increase of 12 percent compared with the $1.011 billion in the
first quarter of 2008. Revenue for the first quarter increased 17
percent after adjusting for th... |
| | | 04/20/09 | St. Jude Medical Announces European Approval of ICDs with Features That Automatically Enhance Patient Safety and Streamline Patient Follow-up| ST. PAUL, Minn.--(BUSINESS WIRE)--Apr. 20, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its AnalyST Accel™ and Current Accel™ ICDs (implantable
cardioverter defibrillators), which automatically adjust therapy to
changing patient needs for increased safety and accelerated follow-up.
The St. Jude Medical Accel family of ICD devices can be programmed to
automatically monitor and adjust the l... |
| | | 04/07/09 | St. Jude Medical's Merlin.net Patient Care Network Wins Medical Design Excellence Award| ST. PAUL, Minn., Apr 07, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) today announced the Merlin.net(TM)
Patient Care Network (PCN) has received a 2009 Medical Design Excellence
Award. Merlin.net PCN is a secure, Internet-based remote care system for
patients with implanted medical devices. This remote care system gathers
and stores data from the implant procedure, in clinic follow-up visits
and from both patient-initiated and automatic remot... |
| | | 04/06/09 | St. Jude Medical Announces First Quarter 2009 Earnings Conference Call| ST. PAUL, Minn., Apr 06, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will hold its quarterly conference
call to discuss First Quarter 2009 results on Wednesday, April 22, at
8:00 a.m. Eastern Time (7:00 a.m. Central Time). A news release will be
issued at 7:30 a.m. Eastern Time (6:30 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over ... |
| | | 03/30/09 | St. Jude Medical and GE Healthcare Announce Worldwide Market Launch of Wireless Integrated FFR Solution| UPPSALA, Sweden & WAUKESHA, Wis. & ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 30, 2009--
St. Jude Medical, Inc. (NYSE:STJ) and GE Healthcare today announced the
worldwide commercial launch of the first fully integrated wireless
solution for the measurement of Fractional Flow Reserve (FFR).
The new FFR solution, seamlessly integrated into existing cathlab
infrastructure, will enable physicians and cathlab staff immediate
access to FFR me... |
| | | 03/26/09 | St. Jude Medical Announces First European Patient Implants of the Libra Deep Brain Stimulation Systems for Parkinson's Disease| ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 26, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced the first patient
implants of its Libra® deep brain stimulation (DBS) system
for treating the symptoms of Parkinson’s disease, a progressive
neurological disorder that affects a person's control over his or her
movements and speech. The announcement was made at the European
Association of Neurosurgical Societies and the Société Française de
Neur... |
| | | 03/16/09 | St. Jude Medical Announces FDA Approval of New Features in Remote Patient Care for Implantable Cardiac Devices| Merlin.net Patient Care Network (PCN) introduces Spanish language capabilities, new patient scheduling tools and expanded alerts for physicians
ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 16, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of the newest version of the Merlin.net™
Patient Care Network (PCN), a secure, Internet-based remote care system
for patients with implanted medical devices. This remote care... |
| | | 03/11/09 | St. Jude Medical Announces European CE Mark Approval of Neurostimulation System for Chronic Angina| ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 11, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its Genesis® neurostimulation system for managing
a form of chest pain known as chronic angina pectoris, or chronic angina.
Approximately the size of a stopwatch, this neurostimulation system
helps to control angina pain by sending mild pulses of electricity from
a device implanted in the torso via thin insulated ... |
| | | 03/09/09 | St. Jude Medical To Present at Cowen and Company Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Mar. 9, 2009--
St. Jude Medical, Inc. (NYSE:STJ) will present at the Cowen and Company
Healthcare Conference on Thursday, March 19, in Boston. John Heinmiller,
executive vice president and chief financial officer, will address the
conference at 10:20 a.m. EDT. The presentation will also be Web cast
live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops medical technology and serv... |
| | | 02/24/09 | St. Jude Medical Receives Australian TGA Regulatory and Reimbursement Approval for the World's Smallest and Longest-Lasting Rechargeable Neurostimulator to Treat Chronic Pain| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 24, 2009--
St. Jude Medical, Inc. (NYSE:STJ) today announced Australian Therapeutic
Goods Administration (TGA) approval of the Eon Mini™ neurostimulator,
the world’s smallest, longest-lasting rechargeable device in its class
to treat chronic pain of the trunk or limbs and pain from failed back
surgery. In Australia, the Eon Mini neurostimulator is reimbursable via
the private health system.
... |
| | | 02/17/09 | St. Jude Medical Welcomes Introduction of Legislation to Help People Suffering From Pain| National Pain Care Policy Act of 2009 would improve treatment of pain, educational outreach, and therapy availability for Americans
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 17, 2009--
St. Jude Medical, Inc. (NYSE:STJ) welcomes the introduction of the
National Pain Care Policy Act of 2009, H.R. 756. Intended to raise
awareness about the growing issue of pain, this legislation is focused
on improving access to patient care in the United States.
Led by ... |
| | | 02/05/09 | St. Jude Medical Announces U.S. Approval of Industry's First Connector System Designed to Simplify Implant Process for Cardiac Resynchronization Therapy Devices| ST. PAUL, Minn.--(BUSINESS WIRE)--
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of the industry’s first medical device
system that allows a single defibrillation lead connection between a
cardiac resynchronization therapy defibrillator (CRT-D) and the wires
(leads) that send electrical impulses to the heart to treat the symptoms
of heart failure.
The new connector system, wh... |
| | | 01/30/09 | St. Jude Medical Announces 2009 Annual Investor Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--
St. Jude Medical, Inc. (NYSE:STJ) will hold its 2009 Annual Investor
Conference on Friday, February 6, 2009, from 8:00 a.m. – 2:30 p.m.
Eastern Time (7:00 a.m. – 1:30 p.m. Central Time).
This presentation will be webcast by CCBN and can be accessed at St.
Jude Medical’s web site at www.sjm.com.
The webcast will also be distributed over CCBN’s Investor Distribution
N... |
| | | 01/27/09 | St. Jude Medical Reports Fourth Quarter and Full-Year 2008 Results|
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE: STJ - News) today reported sales and net earnings
for the fourth quarter and year ended Jan. 3, 2009.
Fourth Quarter and Full-Year SalesThe Company reported net sales of $1.133 billion in the fourth quarter
of 2008, an increase of 11 percent compared to the $1.018 billion in... |
| | | 01/26/09 | St. Jude Medical Announces European CE Mark Approval for Libra Deep Brain Stimulation Systems for Parkinson's Disease| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 26, 2009--St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its Libra(R) and LibraXP(TM) deep
brain stimulation (DBS) systems for treating the symptoms of Parkinson's
disease, a neurological disorder that progressively diminishes a
person's control over his or her movements and speech. The limited
launch of these systems in Europe marks St. Jude Medical's first
products in the DBS ma... |
| | | 01/15/09 | St. Jude Medical Announces Publication of 20-year Durability in Aortic and Mitral Stented Tissue Valves| Study reports excellent long-term durability of the St. Jude Medical Biocor(TM) Stented Tissue Valve for mitral and aortic valve replacement
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 15, 2009--St. Jude Medical, Inc. (NYSE:STJ) today announced the publication of a
study on the St. Jude Medical Biocor(TM) Stented Tissue Valve -
the second study published in recent months to report 20-year data
showing excellent long-term durability of the Biocor tissue valve.
... |
| | | 01/15/09 | St. Jude Medical Announces First Use Outside the U.S. of Imaging System for Real-Time Views inside the Heart| System provides greater physician control during therapeutic and diagnostic procedures
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 15, 2009--St. Jude Medical, Inc. (NYSE:STJ) today announced the first use outside
the United States of its ultrasound imaging system that enables
physicians to view real-time images from inside the heart as they
diagnose and treat conditions resulting from abnormal rhythms or
structural problems. By providing clear, accurate images of the ... |
| | | 01/14/09 | FAME Study Published in New England Journal of Medicine| Routine measurement of fractional flow reserve reduces the risk of death or heart attack by 35 percent after stent placement in patients with multivessel diseaseUPPSALA, Sweden, & ST. PAUL, Minn., Jan 14, 2009 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced the publication of
results from the landmark FAME (Fractional flow reserve (FFR) vs.
Angiography in Multivessel Evaluation) study that demonstrate a
statistically significant 30 percent difference ... |
| | | 01/14/09 | St. Jude Medical Announces Japanese Approval of Atlas II ICD| Powerful, high-energy device is designed to help patients with life-threatening arrhythmias, including patients whose hearts are especially difficult to defibrillate
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 14, 2009--St. Jude Medical, Inc. (NYSE:STJ) today announced regulatory approval
from the Japanese Ministry of Health, Labour and Welfare (MHLW), in
addition to reimbursement approval, of its Atlas(R) II implantable
cardioverter defibrillator (ICD), a device used to tre... |
| | | 01/09/09 | St. Jude Medical Announces Fourth Quarter and Full-Year 2008 Earnings Conference Call| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 9, 2009--St. Jude Medical, Inc. (NYSE: STJ) will hold its quarterly conference
call to discuss Fourth Quarter and Full-Year 2008 results on Tuesday,
January 27, at 8:00 a.m. Eastern Time (7:00 a.m. Central Time). A news
release will be issued at 7:30 a.m. Eastern Time (6:30 a.m. Central
Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
... |
| | | 12/22/08 | St. Jude Medical Acquires MediGuide| New platform technology to enhance St. Jude Medical's atrial fibrillation and other growth programsST. PAUL, Minn. & HAIFA, Israel, Dec 22, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) and MediGuide Inc. today announced
the signing of a definitive merger agreement and simultaneous closing of
the merger whereby St. Jude Medical has acquired all of the outstanding
shares of MediGuide Inc., including the 41.3 percent interest (on a
fully-diluted basis) ... |
| | | 12/21/08 | St. Jude Medical Acquires Radi Medical Systems| Acquisition accelerates expansion of St. Jude Medical's cardiovascular growth platform
ST. PAUL, Minn. & UPPSALA, Sweden--(BUSINESS WIRE)--Dec. 21, 2008--St. Jude Medical, Inc. (NYSE: STJ) and Radi Medical AB announced today
the completion of St. Jude Medical's acquisition of Radi Medical Systems
AB for $250 million in cash.
Radi Medical Systems is the world leader in two segments of the market
for cardiovascular medical devices in which St. Jude Medical ... |
| | | 12/05/08 | St. Jude Medical Announces Neuromodulation Division Name Change, Unveils New Brand Identity at 12th Annual North American Neuromodulation Society Meeting| Key products and multiple poster and oral presentations will be highlighted at Las Vegas conferenceST. PAUL, Minn., Dec 05, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced that its
neuromodulation division, formerly Advanced Neuromodulation Systems, has
adopted the St. Jude Medical name. The St. Jude Medical Neuromodulation
Division unveiled its new brand identity and showcased its flagship
products - including the recently introduced Eon... |
| | | 12/03/08 | St. Jude Medical Announces European Approval and Initial Implant of First Device to Continuously Monitor Electrical Changes That Signal Potential Cardiac Problems| First-of-its-kind device helps to detect cardiac changes, giving physicians unprecedented insight into heart-related events and patient risks
ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 3, 2008--St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its AnalyST(TM) implantable cardioverter
defibrillator (ICD) with ST Monitoring, a revolutionary device that not
only provides life-saving therapy for dangerously fast heart rhythms,
but also contin... |
| | | 12/01/08 | St. Jude Medical Announces Launch of QuickOpt Timing Cycle Optimization for Cardiac Resynchronization Therapy Defibrillators (CRT-D) in Japan| New feature enables physicians to quickly and frequently customize device's timing cycles to meet patient needs ST. PAUL, Minn., Dec 01, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced expanded approval from
the Japanese Ministry of Health, Labour and Welfare for the QuickOpt(R)
Timing Cycle Optimization feature in the Epic(R) HF and Atlas(R)+ HF cardiac
resynchronization therapy defibrillators (CRT-Ds). CRT-Ds are
implantable cardiov... |
| | | 11/25/08 | St. Jude Medical To Present at Piper Jaffray 20th Annual "Unplugged" Health Care Conference| ST. PAUL, Minn., Nov 25, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will present at the Piper Jaffray 20th
Annual "Unplugged" Health Care Conference on Tuesday, Dec. 2, in New
York City. John Heinmiller, executive vice president and chief financial
officer of St. Jude Medical, will address the conference at 11 a.m. EST.
The presentation will also be Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops medical technology... |
| | | 11/17/08 | St. Jude Medical Announces Japanese Approval and Launch of Victory Family of Pacemakers| ST. PAUL, Minn., Nov 17, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced regulatory approval
from the Japanese Ministry of Health, Labour and Welfare (MHLW), in
addition to reimbursement approval, for its Victory(R)
family of pacemakers.
Victory pacemakers are designed to promote more natural heart function,
allowing the patient's own heart rhythm to
prevail when possible by reducing the device's
ventricular pacing using ... |
| | | 10/27/08 | St. Jude Medical Announces Publication of 20-Year Durability Data on Tissue Heart Valve| New study demonstrates excellent long-term durability of St. Jude
Medical Biocor Stented Tissue Valve
ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 27, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced the publication of a study on the St.
Jude Medical Biocor(TM) Stented Tissue Valve that found the valve
provided excellent long-term durability as a replacement for the
aortic valve in patients 65 years and older. The study, which appears
in the October issue of the cardiac journal T... |
| | | 10/15/08 | St. Jude Medical Reports Third Quarter Results| ST. PAUL, Minn.--(BUSINESS WIRE)--
St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net
earnings for the third quarter ended September 27, 2008.
Third Quarter Results
The Company reported net sales of $1.084 billion in the third
quarter of 2008, an increase of 17% compared to the $927 million in
the third quarter of 2007. Favorable foreign currency translation
comparisons increased third quarter sales by approximately $40
million.
Reported net earnings for the... |
| | | 10/14/08 | St. Jude Medical Announces U.S. and European Approval of Angio-Seal Evolution Vascular Closure Device| ST. PAUL, Minn.--(BUSINESS WIRE)--
St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and
Drug Administration (FDA) and European CE Mark approval of the
Angio-Seal(TM) Evolution(TM) Vascular Closure Device. The approval and
global launch was announced at the Transcatheter Cardiovascular
Therapeutics conference in Washington, D.C.
The Angio-Seal Evolution device is designed to enable physicians
to quickly and effectively seal femoral artery punctures made during
minim... |
| | | 10/14/08 | St. Jude Medical Announces European CE Mark Approval of Implantable Device for the Detection of Atrial Fibrillation and Other Abnormal Heart Rhythms| ST. PAUL, Minn.--(BUSINESS WIRE)--
St. Jude Medical, Inc. (NYSE:STJ) today announced it has received
approval for European CE Marking of its SJM Confirm(TM) implantable
cardiac monitor (ICM), a compact device designed to detect atrial
fibrillation (AF) and other abnormal heart rhythms.
About the size of a computer thumb drive, the SJM Confirm ICM is
the smallest implantable cardiac monitor available. It is implanted
just under the skin (subcutaneously) in the upper chest regio... |
| | | 10/07/08 | St. Jude Medical Celebrates the 50th Anniversary of the World's First Implantable Pacemaker| ST. PAUL, Minn.--(BUSINESS WIRE)--
St. Jude Medical, Inc. (NYSE: STJ) today celebrates the 50th
anniversary of the world's first implantable pacemaker. On Oct. 8,
1958, a Swedish man named Arne Larsson received the world's first
implanted pacemaker. The groundbreaking technology for the implantable
cardiac pacemaker was developed by Rune Elmqvist, M.D., of the Swedish
company Elema Schonander, which eventually became part of St. Jude
Medical, whose headquarters are based in St. Paul... |
| | | 10/01/08 | St. Jude Medical Announces Third Quarter 2008 Earnings Conference Call| ST. PAUL, Minn.--(BUSINESS WIRE)--
St. Jude Medical, Inc. (NYSE: STJ) will hold its quarterly
conference call to discuss Third Quarter 2008 results on Wednesday,
October 15 at 8:00 a.m. Eastern Time (7:00 a.m. Central Time). A news
release will be issued at 7:30 a.m. Eastern Time (6:30 a.m. Central
Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distr... |
| | | 09/17/08 | Former U.S. Army Parachutist Becomes First Person Implanted with the World's Smallest Neurostimulator to Treat Chronic Pain| Silver dollar-sized medical device provides injured military
skydiver with pain relief
ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 17, 2008--St. Jude
Medical, Inc. (NYSE:STJ) today announced the first patient implant of
an Eon Mini(TM), the world's smallest, longest-lasting, rechargeable
neurostimulator to treat chronic pain of the trunk or limbs and pain
from failed back surgery.
A 26-year-old patient was implanted with the Eon Mini
neurostimulator, a medical device which is sli... |
| | | 09/11/08 | St. Jude Medical Announces FDA Clearance of Implantable Device to Monitor Cardiac Conditions| New monitor helps physicians detect abnormal heart rhythms in
patients with unexplained symptoms
ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 11, 2008--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) clearance of its SJM Confirm(TM) implantable
cardiac monitor (ICM), a compact device designed to help physicians
diagnose abnormal heart rhythms.
The implantable monitor enables physicians to evaluate heart
rhythm signals over a longer period ... |
| | | 09/02/08 | St. Jude Medical To Present at Morgan Stanley Global Healthcare Unplugged Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 2, 2008--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Morgan Stanley Global Healthcare
Unplugged Conference on Tuesday, Sept. 9, in New York City. John
Heinmiller, executive vice president and chief financial officer, will
address the conference at 11:30 a.m. EDT. The presentation will also
be Web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical develops medical technology and services that
focus on putting mor... |
| | | 08/20/08 | St. Jude Medical Announces FDA Approval of Arecibo Manufacturing Plant| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 20, 2008--St. Jude Medical,
Inc. (NYSE: STJ) today announced U.S. Food and Drug Administration
(FDA) approval of the company's new facility in Arecibo, Puerto Rico,
for the manufacturing of pacemakers and cardiac leads.
The 150,000 square-foot facility, located in Arecibo's Santana
Industrial Park, will initially be used to produce St Jude Medical
pacemakers and cardiac leads for domestic and international markets,
and the company plans to be... |
| | | 08/18/08 | St. Jude Medical Announces CE Mark Approval and FDA Clearance for New Family of HIFU Surgical Ablation Products| Patient at Derriford Hospital in the United Kingdom is the first to undergo treatment ST. PAUL, Minn., Aug 18, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) has received European CE Mark
approval and U.S. Food and Drug Administration (FDA) clearance for the
Epicor(TM) LP Cardiac Ablation System, a second generation technology
that uses HIFU (high intensity focused ultrasound) to surgically
ablate cardiac tissue to disrupt abnormal electrical impulses in the
heart.
The first... |
| | | 08/13/08 | St. Jude Medical Receives U.S. and European Approvals of EonC, the First Extended-Life Primary Cell Neurostimulator for the Treatment of Chronic Pain| New device offers physicians new option for treating pain patients
ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 13, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) and European CE Mark approvals of EonC(TM), the first
extended-life primary cell (non-rechargeable) neurostimulator for the
treatment of chronic pain.
The EonC neurostimulator provides a convenient option for chronic
pain patients who prefer or require the simplicity of a
n... |
| | | 08/06/08 | St. Jude Medical Announces Japanese Approval of the Durata Defibrillation Lead| Next-generation lead designed for ease of implant
ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 6, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced regulatory approval, in addition to
reimbursement approval, from the Japanese Ministry of Health, Labour
and Welfare (MHLW), for the Durata(TM) defibrillation lead, the
company's next-generation high-voltage lead.
The Durata lead incorporates a soft silicone tip with a larger
surface area and a slightly curved right ventricle (RV) ... |
| | | 07/16/08 | St. Jude Medical Reports Second Quarter Results| ST. PAUL, Minn.--(BUSINESS WIRE)--July 16, 2008--St. Jude Medical,
Inc. (NYSE: STJ) today reported sales and net earnings for the second
quarter ended June 28, 2008.
Second Quarter Results
The Company reported net sales of $1.136 billion in the second
quarter of 2008, an increase of 20% compared to the $947 million in
the second quarter of 2007. Favorable foreign currency translation
comparisons increased second quarter sales by approximately $64
million, within the range of ... |
| | | 07/15/08 | St. Jude Medical Announces FDA Approval of Wireless Transmitter to Monitor Patients' Implanted Cardiac Devices| Merlin@home transmitter automatically monitors patients with
implantable cardiac devices and alerts physicians if patients or
devices require attention
ST. PAUL, Minn.--(BUSINESS WIRE)--July 15, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of the Merlin(TM)@home transmitter, an RF wireless
technology that remotely monitors patients' implanted cardiac devices.
The transmitter supports the St. Jude Medical Current(R) RF and... |
| | | 07/10/08 | St. Jude Medical Announces CE Mark Approval and European Launch of HydroSteer Guidewire Line with Hydrophilic Coating| ST. PAUL, Minn.--(BUSINESS WIRE)--July 10, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced European CE Mark approval and European
launch of its line of HydroSteer(TM) Hydrophilic-Coated Nitinol
Guidewires.
The HydroSteer line of guidewires features a lubricious
hydrophilic coating which becomes slippery when wet, thereby reducing
friction and enabling physicians to more easily maneuver the wires
through the patient's vessels. The HydroSteer line includes a wide
variety of... |
| | | 07/07/08 | St. Jude Medical Completes Acquisition of EP MedSystems and Announces Final Prorated Results of EP MedSystems Shareholder Cash/Stock Elections| ST. PAUL, Minn.--(BUSINESS WIRE)--July 7, 2008--St. Jude Medical,
Inc. (NYSE: STJ) announced today that it has completed the previously
announced acquisition of EP MedSystems, Inc.
"We are pleased to have completed this transaction, which enables
us to further enhance St. Jude Medical's program to help physicians
cure atrial fibrillation," said Daniel J. Starks, chairman, president
and chief executive officer of St. Jude Medical.
In addition, St. Jude Medical announced the fin... |
| | | 07/02/08 | CORRECTING and REPLACING St. Jude Medical and EP MedSystems Announce Final Exchange Ratio for Pending Acquisition| ST. PAUL, Minn. & WEST BERLIN, N.J.--(BUSINESS WIRE)--July 2,
2008--In BW5144 issued July 2, 2008: In the fourth paragraph of the
release, the first sentence should read: As previously announced, the
Election Deadline was 5 p.m. EDT, July 1, 2008 (sted As previously
announced, the Election Deadline was 5 p.m. EDT, today, July 1, 2008).
The corrected release reads:
ST. JUDE MEDICAL AND EP MEDSYSTEMS ANNOUNCE FINAL EXCHANGE RATIO
FOR PENDING ACQUISITION
St. Jude M... |
| | | 07/02/08 | St. Jude Medical and EP MedSystems Announce Final Exchange Ratio for Pending Acquisition| ST. PAUL, Minn. & WEST BERLIN, N.J.--(BUSINESS WIRE)--July 2,
2008--St. Jude Medical, Inc. (NYSE: STJ) and EP MedSystems, Inc.
(NASDAQ: EPMD) announced today that in connection with the previously
announced acquisition of EP MedSystems by St. Jude Medical, the final
exchange ratio is 0.0738 (rounded) for the stock portion of the
consideration.
As previously announced, under the terms of the agreement, EP
MedSystems shareholders will receive either $3.00 in cash or
approximately $... |
| | | 06/27/08 | St. Jude Medical Announces Second Quarter 2008 Earnings Conference Call| ST. PAUL, Minn., Jun 27, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will hold its quarterly
conference call to discuss Second Quarter 2008 results on Wednesday,
July 16th at 8:00 a.m. Eastern Time (7:00 a.m. Central Time). A news
release will be issued at 7:30 a.m. Eastern Time (6:30 a.m. Central
Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribut... |
| | | 06/26/08 | St. Jude Medical and EP MedSystems Announce Cash/Stock Election Deadline and Expected Closing Date of Pending Acquisition| ST. PAUL, Minn. & WEST BERLIN, N.J.--(BUSINESS WIRE)--June 26,
2008--St. Jude Medical, Inc. (NYSE: STJ) and EP MedSystems, Inc.
(NASDAQ: EPMD) announced today that the deadline for EP MedSystems
shareholders to elect the form of consideration they wish to receive
in connection with the previously announced acquisition of EP
MedSystems by St. Jude Medical will be 5 p.m. EDT, on July 1, 2008
(the Election Deadline). The transaction is scheduled to close on
July 3, 2008, provided that th... |
| | | 06/26/08 | St. Jude Medical Announces First Patient Implants in Clinical Study Evaluating Deep Brain Stimulation for Depression| ST. PAUL, Minn.--(BUSINESS WIRE)--June 26, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced the first patient implants in a
clinical study that is investigating whether deep brain stimulation
(DBS) therapy will help people who suffer from major depressive
disorder, a severe form of depression. The patients, a 59-year-old
woman and a 42-year-old man, were implanted at Alexian Brothers
Behavioral Health Hospital in Chicago, with the St. Jude Medical
Libra(R) Deep Brain Stimulatio... |
| | | 06/04/08 | St. Jude Medical Announces CE Mark Approval and European Launch of TigerWire Steerable Guidewire| ST. PAUL, Minn., Jun 04, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) today announced European CE
Mark approval and the European launch of the TigerWire(TM) Steerable
Guidewire. The announcement was made in Barcelona, Spain, at EuroPCR
2008, a premiere scientific and professional event for cardiologists,
vascular surgeons and other medical specialists who perform
interventional procedures such as angioplasty and stenting to treat
cardiovascular diseases.
The newest member of... |
| | | 05/15/08 | Results from Studies Evaluating High-Voltage Lead Performance Presented at Heart Rhythm Society's 29th Annual Scientific Sessions| Four prospective studies with comprehensive record monitoring
analyze 7,498 patients with Riata leads
ST. PAUL, Minn.--(BUSINESS WIRE)--May 15, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced that results were presented from the
largest actively monitored, multi-site lead performance evaluation
ever conducted for an ICD lead family. The data presented is from an
analysis of four prospective studies, all with comprehensive data
monitoring on the performance of the Riata(R) ... |
| | | 05/15/08 | St. Jude Medical Announces FDA Clearance and European CE Mark Approval for Tools That Help Place Leads in Challenging Heart Anatomy| Delivery tools designed to provide access to optimal, but
difficult-to-reach, positions
ST. PAUL, Minn.--(BUSINESS WIRE)--May 15, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance and European CE Mark approval of new delivery tools
designed to give physicians greater control and precision when placing
cardiac pacing leads in challenging heart anatomy. The CPS Duo(TM)
stylet and guidewire system and the CPS Courier(TM) guidewi... |
| | | 05/14/08 | St. Jude Medical Announces Launch of New Circular Mapping Catheter| ST. PAUL, Minn., May 14, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced the U.S. launch
of the Reflexion Spiral X(TM) variable radius mapping catheter at
Heart Rhythm 2008. This new catheter will provide physicians with
greater maneuverability, stability and control when used in the left
atrium for the mapping of abnormal atrial heart arrhythmias, including
Atrial Fibrillation (AF).
Circular mapping catheters are designed to measure electrical
activity at the op... |
| | | 05/13/08 | St. Jude Medical Announces FDA and European CE Mark Approvals of the IsoFlex Optim Pacing Lead| Optim insulation now available in all St. Jude Medical pacemaker
and ICD leads
ST. PAUL, Minn.--(BUSINESS WIRE)--May 13, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) and European CE Mark approvals of the IsoFlex(R) Optim(TM)
pacing lead. The small-diameter lead is built on the proven IsoFlex(R)
pacing lead platform, and features the company's exclusive Optim(R)
insulation material. With the addition of Optim insulation to IsoFlex
... |
| | | 05/13/08 | St. Jude Medical Announces Start of Landmark DETERMINE ICD Study| Clinical trial will investigate effectiveness of implantable cardioverter defibrillator therapy in heart attack patientsST. PAUL, Minn., May 13, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced the initial
enrollments into a new landmark clinical trial designed to better
identify which patients could benefit from implantable cardioverter
defibrillator (ICD) therapy for the prevention of sudden cardiac
arrest (SCA).
The DETERMINE (Defibrillators To Reduce Risk by Mag... |
| | | 05/12/08 | St. Jude Medical Announces FDA Approval of Next-Generation Remote Monitoring and Data Management System for Implantable Cardiac Devices| Merlin.net Patient Care Network contacts patients with automated
interactive voice response system
ST. PAUL, Minn.--(BUSINESS WIRE)--May 12, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of the next-generation Merlin(TM).net Patient Care
Network (PCN), an Internet-based central repository for patient device
data gathered at the time of implant procedures, at in-clinic
follow-up visits or from patient-initiated remote follo... |
| | | 05/12/08 | St. Jude Medical Announces the Release of EnSite System Version 8.0 Software| ST. PAUL, Minn.--(BUSINESS WIRE)--May 12, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced the release of its EnSite(TM) System
Version 8.0 software. The new software will help physicians more
intuitively visualize the anatomy of the heart to diagnose and treat
abnormal heart rhythms. St. Jude Medical will feature the EnSite v.8.0
at Heart Rhythm 2008 on May 14 - 17.
The EnSite System is used in minimally invasive electrophysiology
(EP) procedures. Catheters with electrodes... |
| | | 05/09/08 | CORRECTING and REPLACING St. Jude Medical Announces Results of Shareholders' Vote at Annual Meeting| ST. PAUL, Minn., May 09, 2008 (BUSINESS WIRE) -- Second paragraph should read: In addition, shareholders approved
certain amendments to the St. Jude Medical, Inc. 2007 Stock Incentive
Plan, ratified the appointment of Ernst & Young LLP as the Company's
Independent Registered Public Accounting Firm, and approved an
amendment to the articles of incorporation to implement a majority
voting standard for directors in uncontested elections. (sted In
addition, shareholders approved certain am... |
| | | 05/09/08 | St. Jude Medical Announces Results of Shareholders' Vote at Annual Meeting| ST. PAUL, Minn., May 09, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) announced at its annual meeting
of shareholders today that Richard R. Devenuti, Stuart M. Essig,
Thomas H. Garrett and Wendy Yarno were re-elected to the Company's
Board of Directors for three-year terms.
In addition, shareholders approved certain amendments to the St.
Jude Medical, Inc. 2007 Stock Incentive Plan and the St. Jude Medical,
Inc. 2007 Employee Stock Purchase Plan, ratified the appointment of
E... |
| | | 05/09/08 | St. Jude Medical to Launch New Brand Identity| The new brand identity will combine the company's commitment to meeting customer needs with its reputation for qualityST. PAUL, Minn., May 09, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) today announced it will unveil
its new corporate identity to physician customers at the 88th Annual
Meeting of the American Association of Thoracic Surgery (AATS) on May
10, at EuroPCR on May 13 and at the Heart Rhythm Society's (HRS)
Annual Scientific Sessions on May 14. The new brand identit... |
| | | 05/07/08 | St. Jude Medical Announces FDA Clearance and CE Mark Approval of Strada Carotid Guiding Sheath| ST. PAUL, Minn.--(BUSINESS WIRE)--May 7, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance and European CE Mark approval of the Strada(TM)
Carotid Guiding Sheath, a flexible tube through which physicians can
deliver balloon catheters, stents and other tools to open blockages in
the carotid arteries. The Strada Carotid Guiding Sheath is designed
specifically to provide easier and faster access to challenging
carotid anatomy.
... |
| | | 05/05/08 | Results of Brodmann Area 25 Deep Brain Stimulation Pilot Study Offer Hope for Patients with Severe Depression| Study findings presented today at American Psychiatric Association
Annual Meeting
ST. PAUL, Minn.--(BUSINESS WIRE)--May 5, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced pilot study results from the first
multi-center study investigating deep brain stimulation (DBS) of
Brodmann Area 25 for major depressive disorder.
Results of the study, which were presented today at the American
Psychiatric Association (APA) meeting in Washington, D.C., found that
6 month... |
| | | 05/02/08 | St. Jude Medical and Microsoft Collaborate to Provide Patients and Physicians with Better Access to Health Records|
Integration of St. Jude Medical network and Microsoft HealthVault
will enable patients to easily share cardiac device data with
physicians
ST. PAUL, Minn.--(BUSINESS WIRE)--May 2, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced a partnership with the Microsoft Corp.
Health Solutions Group to research the integration of data from
implantable devices with patient-controlled, personal health records.
St. Jude Medical and Microsoft will w... |
| | | 04/30/08 | St. Jude Medical Announces U.S. Launch of TigerWire Steerable Guidewire| ST. PAUL, Minn.--(BUSINESS WIRE)--April 30, 2008--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. launch of the
TigerWire(TM) Steerable Guidewire. The newest member of the St. Jude
Medical GuideRight(TM) family of steerable guidewires, the TigerWire
Steerable Guidewire is designed to enhance physicians' ability to
steer through challenging peripheral arteries, the vessels that supply
blood to the legs and arms.
A guidewire is a thin, flexible wire that physicians use to hel... |
| | | 04/23/08 | St. Jude Medical to Present at Morgan Stanley Global Healthcare Unplugged Conference| ST. PAUL, Minn., Apr 23, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will present at the Morgan
Stanley Global Healthcare Unplugged Conference on Wednesday, April 30,
2008, in Key Biscayne, FL. Dan Starks, Chairman, President & Chief
Executive Officer, will address the conference at 3:40 p.m. ET. The
presentation will also be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain p... |
| | | 04/21/08 | St. Jude Medical Awarded U.S. Patent for Neurostimulation Therapy for Depression| Brodmann Area 25 Study Moves Forward With Enrollment of First
Patient
ST. PAUL, Minn.--(BUSINESS WIRE)--April 21, 2008--St. Jude
Medical, Inc. (NYSE:STJ) today announced it has been awarded a patent
from the U.S. Patent and Trademark Office for treating depression
using neurostimulation therapy in an area of the brain known as
Brodmann Area 25.
Brodmann Area 25 is a structure within the subcollosal gyrus
region of the brain. It is the focus of ... |
| | | 04/16/08 | St. Jude Medical Reports First Quarter Results| ST. PAUL, Minn.--(BUSINESS WIRE)--April 16, 2008--St. Jude
Medical, Inc. (NYSE: STJ) today reported sales and net earnings for
the first quarter ended March 29, 2008.
First Quarter Results
The Company reported net sales of $1.011 billion in the first
quarter of 2008, an increase of 14% compared to the $887 million in
the first quarter of 2007. Favorable foreign currency translation
comparisons increased first quarter sales by approximately $45
million.
Reported net earni... |
| | | 04/14/08 | St. Jude Medical Receives FDA and CE Mark Approvals for the World's Smallest, Longest-Lasting Rechargeable Neurostimulator to Treat Chronic Pain| Eon Mini Combines Greater Patient Comfort With 10-Year Battery
Longevity
ST. PAUL, Minn.--(BUSINESS WIRE)--April 14, 2008--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) and European CE Mark approvals of Eon Mini((TM)),
the world's smallest, longest-lasting rechargeable neurostimulator to
treat chronic pain of the trunk or limbs and pain from failed back
surgery.
Slightly larger than the circumference o... |
| | | 04/09/08 | St. Jude Medical to Acquire EP MedSystems| Transaction Will Accelerate St. Jude Medical's Atrial Fibrillation
Program
ST. PAUL, Minn. & WEST BERLIN, N.J.--(BUSINESS WIRE)--April 9,
2008--St. Jude Medical, Inc. (NYSE: STJ) and EP MedSystems, Inc.
(NASDAQ: EPMD) announced today that the Boards of Directors of both
companies have unanimously approved a definitive merger agreement
under which St. Jude Medical will acquire EP MedSystems for
approximately $92.1 million.
Terms of the Agreement
Under the terms o... |
| | | 04/04/08 | St. Jude Medical Announces First Quarter 2008 Earnings Conference Call| ST. PAUL, Minn.--(BUSINESS WIRE)--April 4, 2008--St. Jude Medical,
Inc. (NYSE:STJ) will hold its quarterly conference call to discuss
First Quarter 2008 results on Wednesday, April 16th at 9:00 a.m.
Eastern Time (8:00 a.m. Central Time). A news release will be issued
at 8:00 a.m. Eastern Time (7:00 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over CCBN's Inves... |
| | | 04/02/08 | St. Jude Medical Announces Japanese Approval of the Merlin Programmer for Pacemakers, ICDs and CRT Devices| New programmer will provide quick and easy device programming
ST. PAUL, Minn.--(BUSINESS WIRE)--April 2, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced regulatory approval from the Japanese
Ministry of Health, Labour and Welfare (MHLW) for the Merlin(TM)
Patient Care System, a universal programmer for cardiac
resynchronization therapy (CRT) devices, implantable cardioverter
defibrillators (ICDs) and pacemakers. The System is designed to allow
quick and efficient programmi... |
| | | 03/10/08 | St. Jude Medical Announces Japanese Approval and Launch of Tailor Flexible Ring and Band for Heart Valve Repair| ST. PAUL, Minn.--(BUSINESS WIRE)--March 10, 2008--St. Jude
Medical, Inc. (NYSE:STJ) today announced regulatory approval from the
Ministry of Health, Labor and Welfare (MHLW), in addition to
reimbursement approval, of the SJM Tailor(R) Flexible Ring and SJM
Tailor(R) Flexible Band, the company's first products in Japan for
repairing diseased heart valves.
The Tailor Flexible Ring and the C-shaped Tailor Flexible Band are
designed to provide surgeons with a range of easy-to-implant ... |
| | | 03/07/08 | St. Jude Medical to Present at Eleventh Annual Lehman Brothers Global Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--March 7, 2008--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Lehman Brothers Global Healthcare
Conference on Wednesday, March 19, 2008, in Miami. Dan Starks,
Chairman, President & Chief Executive Officer, will address the
conference at 3:45 p.m. ET. The presentation will also be web cast
live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain pa... |
| | | 03/03/08 | St. Jude Medical Named FORTUNE Magazine's Most Admired Medical and Other Precision Equipment Company for Second Consecutive Year| ST. PAUL, Minn.--(BUSINESS WIRE)--March 3, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced that FORTUNE Magazine has named it one
of "America's Most Admired Companies" for 2008. St. Jude Medical
ranked No. 1 in the Medical and Other Precision Equipment category for
the second year in a row.
St. Jude Medical has been named to FORTUNE's Most Admired
Companies list in each of the last four years.
"We are honored to again be recognized among America's most
admired compani... |
| | | 02/25/08 | St. Jude Medical Announces Share Repurchase Program Authorization| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 25, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced that its Board of Directors has
authorized the Company to repurchase up to $250 million of its common
stock. Purchases may be made in the open market, in privately
negotiated transactions or otherwise. The manner, timing and amount of
any purchases will be determined by the Company's management based on
their evaluation of market conditions, stock price and other factors.
All purchases w... |
| | | 02/14/08 | St. Jude Medical Receives FDA and CE Mark Approvals of Extended 10-Year Battery Life Claim for Rechargeable Neurostimulator| Eon Neurostimulation System provides chronic pain patients with
longest-lasting battery available
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 14, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) and European CE Mark approvals of a 10-year battery longevity
claim for the Eon(R) neurostimulator, a rechargeable device used to
treat chronic pain. The announcement was made today at the 24th annual
meeting of the American Acad... |
| | | 02/07/08 | St. Jude Medical Announces Clinical Study of Deep Brain Stimulation for Depression| Research to focus on the Brodmann Area 25 region of the brain
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 7, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced it has received an Investigational
Device Exemption (IDE) from the U.S. Food and Drug Administration
(FDA) to begin enrollment in a controlled, multi-site, blinded,
clinical study of deep brain stimulation for major depressive
disorder, a severe form of depression.
The BROADEN(TM) (BROdmann Area 25 DEep brain Neuromodul... |
| | | 02/05/08 | St. Jude Medical Announces European CE Mark Approval of Integrated Irrigation Pump and Cardiac Ablation Generator| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 5, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced European CE Mark approval of two
integrated components: the Cool Point(TM) Irrigation Pump and the
IBI-1500T11 Cardiac Ablation Generator. Designed to enhance
physicians' ability to perform successful cardiac ablations, the
integrated components were developed for use together with the St.
Jude Medical family of Therapy(TM) Cool Path(TM) irrigated catheters.
Catheter ablation therapy ... |
| | | 02/01/08 | St. Jude Medical Announces 2008 Annual Investor Conference| ST. PAUL, Minn., Feb 01, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will hold its 2008 Annual
Investor Conference on Friday, February 8, 2008, from 8:00 a.m. - 2:30
p.m. Eastern Time (7:00 a.m. - 1:30 p.m. Central Time).
This call will be webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast will also be distributed over CCBN's Investor
Distribution Network to both institutional and individual investors.
Individual investors can li... |
| | | 01/25/08 | Company Profile for St. Jude Medical| --(BUSINESS WIRE)--St. Jude Medical is dedicated to making life
better for cardiac, neurological and chronic pain patients worldwide
through excellence in medical device technology and services. The
Company has five major focus areas that include: cardiac rhythm
management, atrial fibrillation, cardiac surgery, cardiology and
neuromodulation. Headquartered in St. Paul, Minn., St. Jude Medical
employs approximately 12,000 people worldwide. For more information,
please visit www.sjm.com... |
| | | 01/25/08 | Independent Clinical Trial Finds HIFU Surgical Ablation Effective in Treating Atrial Fibrillation| Annals of Thoracic Surgery publishes results showing 83 percent
efficacy rate
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 25, 2008--An independent
investigator clinical trial has shown atrial fibrillation (AF) is
effectively treated using the Epicor(TM) Cardiac Ablation System, when
treated concomitantly to corrective heart surgery. The trial results
were published in the December edition of The Annals of Thoracic
Surgery. St. Jude Medical, Inc. (NYSE:STJ) ... |
| | | 01/23/08 | St. Jude Medical Reports Fourth Quarter and Full-Year 2007 Results| Company Records First $1 Billion Revenue Quarter ST. PAUL, Minn., Jan 23, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today reported sales and net
earnings for the fourth quarter and full-year ended Dec. 29, 2007.
Fourth Quarter and Full-Year Sales
The Company reported net sales of $1.018 billion in the fourth
quarter of 2007, representing the Company's first ever $1 billion
quarter, $41 million above the high end of the Company's guidance and
an increase of 18% compare... |
| | | 01/22/08 | St. Jude Medical Announces the Renewal of Complete Line of Cardiovascular Purchase Agreements with HealthTrust Purchasing Group| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 22, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced that it has renewed its complete line
of product agreements with HealthTrust Purchasing Group, LP
(HealthTrust). The renewal will extend through December 2010 all
existing purchasing agreements between the parties, which cover St.
Jude Medical's complete line of Cardiac Rhythm Management, Atrial
Fibrillation, Cardiac Surgery and Cardiology products.
"We are excited to continue our ... |
| | | 01/22/08 | St. Jude Medical Announces FDA Approval of Next Generation Internet-Based Data Management System for Implantable Cardiac Devices| Merlin .net Patient Care Network provides physicians with improved
access to important patient device data
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 22, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of software and firmware updates to the Merlin(TM).net
Patient Care Network (PCN). The new Merlin.net PCN 2.5 will expand
availability of the system nationwide and provide physicians with
improved options for remotely moni... |
| | | 01/22/08 | St. Jude Medical Announces FDA and European CE Mark Approval of the QuickFlex Family of Leads| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 22, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) and European CE Mark approval of the QuickFlex(TM) family of
left-heart leads to treat heart failure patients.
The QuickFlex leads, used in CRT (cardiac resynchronization
therapy), feature shorter tip and ring electrodes (used to conduct
energy), reducing the length of the lead's rigid portions. The concept
behind the shorter electrodes is that... |
| | | 01/18/08 | St. Jude Medical Distributes Programmer Software Upgrade to Eliminate Low-Frequency Anomaly| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 18, 2008--St. Jude Medical,
Inc. (NYSE: STJ) today announced that it has distributed a programmer
software upgrade to eliminate a random, low-frequency anomaly that
could affect ventricular sensing in the Epic(TM) and Atlas(TM)
families of implantable cardiac defibrillators.
Specifically, a potential loss of ventricular sensing has been
attributed to an extremely rare timing sequence that occurs in a very
small (61 microsecond) timing window.... |
| | | 01/17/08 | St. Jude Medical Announces FDA and European CE Mark Approvals of Durata Defibrillation Lead| Next Generation Lead Focuses on Ease of Implantation
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 17, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) and European CE Mark approvals of the Durata(TM) defibrillation
lead, the company's next generation high voltage lead. The
announcement was made at the 13th Annual International Boston Atrial
Fibrillation Symposium in Boston, Mass.
Durata features a soft silicone tip with a larger surface... |
| | | 01/16/08 | St. Jude Medical Announces U.S. Clearance for Cardiac Image Integration Software| New imaging tool combines CT with EnSite System cardiac models for
superior imaging
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 16, 2008--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance for its EnSite Fusion(TM) Registration Module. The new
software will help physicians create detailed heart models to
facilitate the diagnosis and delivery of therapy for complex abnormal
atrial heart rhythms, including Atrial Fibrillation (AF).
... |
| | | 01/04/08 | St. Jude Medical Announces Fourth Quarter and Full-Year 2007 Earnings Conference Call| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 4, 2008--St. Jude Medical,
Inc. (NYSE: STJ) will hold its quarterly conference call to discuss
Fourth Quarter and Full-Year 2007 results on January 23rd at 9:00 a.m.
Eastern Time (8:00 a.m. Central Time). A news release will be issued
at 8:00 a.m. Eastern Time (7:00 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over CCBN's Inv... |
| | | 01/02/08 | St. Jude Medical to Present at JPMorgan Healthcare Conference| ST. PAUL, Minn., Jan 02, 2008 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will present at the JPMorgan
Healthcare Conference on Tuesday, January 8, 2008, in San Francisco.
Dan Starks, Chairman, President & Chief Executive Officer, will
address the conference at 10:00 a.m. PST. The presentation will be web
cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients worldwide through exce... |
| | | 12/10/07 | St. Jude Medical Elects Barbara B. Hill to Board of Directors| ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 10, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced the election of Barbara B. Hill to its
board of directors, effective immediately. Ms. Hill is currently the
chief executive officer and president of ValueOptions, Inc., a
privately owned managed behavioral health company, where she also
serves as a board member.
Ms. Hill has approximately 30 years of experience within the
healthcare industry, including past roles as president of Expr... |
| | | 11/26/07 | St. Jude Medical Announces FDA Approval of Epic Stented Tissue Valve with Anti-Calcification Technology| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 26, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of its Epic(TM) Stented Tissue Valve with Linx(TM) AC
Technology. Identical in design to the company's Biocor(TM) Valve,
which currently leads the tissue valve industry in U.S. market share
growth, the Epic Valve also incorporates patented anti-calcification
technology designed to protect against tissue mineralization, or
hardening.
A... |
| | | 11/12/07 | Response Submitted to PACE Affirming Performance of Riata Leads| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 12, 2007--St. Jude Medical,
Inc. (NYSE:STJ) said that an article was submitted to Pacing and
Clinical Electrophysiology (PACE) journal responding to an editorial
concerning the Riata family of leads that is expected to be published
on the PACE Web site today. The article, authored by Mark D. Carlson
M.D., Roger A. Freedman M.D., and Paul A. Levine M.D., has been
accepted and is expected to be published by PACE in the December
issue.
In reaff... |
| | | 11/06/07 | St. Jude Medical Announces Results from RethinQ Clinical Trial| Data Provide Further Information about Indications for Cardiac
Resynchronization Therapy
ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 6, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced that the Resynchronization Therapy In
Normal QRS (RethinQ) Trial, which studied a subgroup of heart failure
patients, most of whom are currently not indicated for cardiac
resynchronization therapy (CRT), did not reach its primary
effectiveness endpoint of improved oxygen con... |
| | | 11/06/07 | St. Jude Medical Announces One-Year Results from MASCOT Trial| ST. PAUL, Minn., Nov 06, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced the one-year
results from its 409-patient Management of Atrial Fibrillation
Suppression in AF-HF Comorbidity Therapy (MASCOT) trial. The findings
were presented during a late-breaking clinical trials session of the
American Heart Association Scientific Sessions 2007 in Orlando, Fla.
The MASCOT trial was designed to determine whether the St. Jude
Medical Atrial Fibrillation (AF) Suppression pa... |
| | | 10/29/07 | St. Jude Medical to Participate in Conference Call Panel Hosted by Bear Stearns| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 29, 2007--St. Jude Medical,
Inc. (NYSE:STJ) will participate in a conference call panel hosted by
Rick Wise, Medical Supplies & Devices analyst with Bear Stearns, today
at 3 p.m. ET.
Eric Fain, president of St. Jude Medical's Cardiac Rhythm
Management Division, will participate in the panel entitled "Small
Leads - Design Matters. Asking the Tough Questions of Physicians and
St. Jude Medical." The call will be webcast live at www.sjm.com.
... |
| | | 10/18/07 | St. Jude Medical Reports Third Quarter Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 18, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today reported sales and net earnings for the third
quarter ended September 29, 2007.
Third Quarter Results
The Company reported net sales of $927 million in the third
quarter of 2007, an increase of 13% compared to the $821 million in
the third quarter of 2006. Favorable foreign currency translation
comparisons increased third quarter sales by approximately $20
million.
Reported net earni... |
| | | 10/11/07 | St. Jude Medical Awarded Contract for Cardiac Rhythm Management Devices| One of the nation's largest group-purchasing organizations,
Premier Purchasing Partners, L.P., selects St. Jude Medical as one of
three CRM suppliers
ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 11, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced that it has been awarded a Cardiac
Rhythm Management (CRM) contract with Premier Purchasing Partners,
L.P., one of the nation's largest healthcare purchasing alliances.
St. Jude Medical was one of three CRM manufacturers to receive... |
| | | 10/08/07 | St. Jude Medical to Expand Organizational Structure to Support Continued Growth| Seven Executives Appointed to New Roles
ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 8, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced an expanded organizational structure
and the appointment of several key executives to new roles, effective
Jan. 1, 2008. These organizational changes will support the Company's
continued growth and capitalize on St. Jude Medical's management
depth.
Dan Starks, Chairman, President and Chief Executive Officer of St.
Jude Medical, said, "Durin... |
| | | 09/25/07 | St. Jude Medical Named to BusinessWeek Magazine's ''Best Places to Launch a Career'' List| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 25, 2007--St. Jude
Medical, Inc. (NYSE:STJ) today announced that BusinessWeek magazine
has named it one of "The Best Places to Launch a Career" in 2007. St.
Jude Medical was ranked number 44 out of 95 companies in the U.S. that
made the list.
"St. Jude Medical is delighted to be recognized for our efforts in
welcoming recent graduates into our company," said Daniel J. Starks,
chairman, president and CEO of St. Jude Medical. "We are also ve... |
| | | 09/25/07 | St. Jude Medical Announces Third Quarter 2007 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--Sept. 25, 2007--St. Jude Medical,
Inc. (NYSE: STJ) will hold its quarterly conference call to discuss
Third Quarter 2007 results on October 18th at 9:00 a.m. Eastern Time
(8:00 a.m. Central Time). A news release will be issued at 8:00 a.m.
Eastern Time (7:00 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distributi... |
| | | 09/18/07 | St. Jude Medical Announces FDA Approval of Company's First Radiofrequency Wireless ICD and CRT-D Heart Failure Devices| First Devices Built on Company's New Consolidated Platform
ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 18, 2007--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of its first radiofrequency (RF)
wireless devices to treat patients with heart failure and with
potentially lethal heart arrhythmias. The Promote(TM) RF CRT-D
(cardiac resynchronization therapy defibrillator) and Current(TM) RF
ICD (implantable cardioverter defibrillator) feat... |
| | | 09/14/07 | St. Jude Medical to Present at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 14, 2007--St. Jude
Medical, Inc. (NYSE:STJ) will present at the Merrill Lynch Global
Pharmaceutical, Biotech & Medtech Conference on Wednesday, September
19, 2007, in London, UK. John C. Heinmiller, Executive Vice President
and Chief Financial Officer, will address the conference at 6:20 a.m.
EST (11:20 a.m. London time). The presentation will be web cast live
at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to makin... |
| | | 08/21/07 | St. Jude Medical Announces Japanese Approval of the Angio-Seal STS Plus Vascular Closure Device| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 21, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced regulatory approval from the Ministry
of Health, Labor and Welfare (MHLW), in addition to reimbursement
approval, for the Angio-Seal(TM) STS Plus Vascular Closure device.
Angio-Seal STS Plus is designed to provide physicians with an
improved method of sealing catheterization sites, allowing patients
increased comfort and offering hospitals improved efficiencies.
Approved for both per... |
| | | 07/26/07 | St. Jude Medical Receives FDA Clearance for ACross Transseptal Access System| New device increases control and reduces complexity of critical step in accessing the left atriumST. PAUL, Minn., Jul 26, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and
Drug Administration (FDA) clearance and a Health Canada License for
the ACross(TM) Transseptal Access System, a device that improves
control and simplifies the procedure physicians use to access the left
atrium during complex cardiac procedures such as atrial fibrillation
ablation.
T... |
| | | 07/25/07 | St. Jude Medical Announces FDA Clearance of the Proxis Embolic Protection System| Proxis is Industry's First "Upstream" Embolic Protection System
ST. PAUL, Minn.--(BUSINESS WIRE)--July 25, 2007--St. Jude Medical,
Inc., (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance of the 7F Proxis(TM) Embolic Protection System.
The Proxis Embolic Protection System is intended to extract debris
that may become dislodged when an intervention, such as delivering a
stent, is performed on patients who have previously undergone a heart
bypass proced... |
| | | 07/24/07 | St. Jude Medical Announces First Clinical Trial Implant of Trifecta Stented Tissue Heart Valve| ST. PAUL, Minn., Jul 24, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced the first
patient implant in its clinical trial of Trifecta(TM), a new
investigational stented, pericardial tissue heart valve.
The patient is the first of approximately 500 adult patients who
will participate in the study. The first implant was performed by
Hartzell V. Schaff, M.D., chair, Cardiovascular Surgery Division, Mayo
Clinic, Rochester, Minn., and the trial's principal investigator.... |
| | | 07/18/07 | St. Jude Medical Reports Second Quarter Results| ST. PAUL, Minn.--(BUSINESS WIRE)--July 18, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today reported sales and net earnings for the second
quarter ended June 30, 2007.
Second Quarter Results
The Company reported net sales of $947 million in the second
quarter of 2007, an increase of 14% compared to the $833 million in
the second quarter of 2006. Favorable foreign currency translation
comparisons increased second quarter sales by approximately $21
million.
Reported net earni... |
| | | 07/16/07 | St. Jude Medical Announces Japanese Approval of CRT-D Products to Treat Heart Failure Patients| Two New Systems to be Available in Japan
ST. PAUL, Minn.--(BUSINESS WIRE)--July 16, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced regulatory approval from the Ministry
of Health, Labor and Welfare (MHLW), in addition to reimbursement
approval, for the Company's first CRT-D systems in Japan to treat
heart failure patients.
Two new systems used to treat heart failure patients have been
approved, including the Atlas(R)+ HF CRT-D (cardiac resynchronization
therapy defib... |
| | | 07/09/07 | St. Jude Medical Announces First Enrollment in Study To Understand Appropriate Anti-Clotting Therapy After Tissue Heart Valve Implant| ST. PAUL, Minn.--(BUSINESS WIRE)--July 9, 2007--St. Jude Medical,
Inc. (NYSE:STJ) and the Duke Clinical Research Institute (DCRI) today
announced the first enrollment in a major study designed to better
understand appropriate anti-clotting medication therapies for patients
following implantation of tissue heart valves.
The study will gather extensive clinical evidence on the use of
anti-coagulant and anti-platelet (blood-thinning) medication
treatments to reduce the risk of clot f... |
| | | 07/06/07 | St. Jude Medical Announces Second Quarter 2007 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--July 6, 2007--St. Jude Medical, Inc.
(NYSE: STJ) will hold its quarterly conference call to discuss Second
Quarter 2007 results on July 18th at 8:15 a.m. Eastern Time (7:15 a.m.
Central Time). A news release will be issued at 7:30 a.m. Eastern Time
(6:30 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribution N... |
| | | 06/28/07 | St. Jude Medical Announces FDA and CE Mark Approvals Of QuickOpt Timing Cycle Optimization For Additional Heart Failure Devices| Approval provides timing-cycle optimization to more patients worldwide
ST. PAUL, Minn.--(BUSINESS WIRE)--June 28, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) and European CE Mark approvals to expand the capabilities of its
Frontier(R) II cardiac resynchronization therapy pacemaker (CRT-P) to
include QuickOpt(TM) Timing Cycle Optimization, giving physicians a
new option to manage therapy for patients based on their individual
need... |
| | | 06/22/07 | St. Jude Medical Announces CE Mark Approval of OptiSense Pacing Lead| New Lead Clinically Proven to Improve Implantable Device Therapy;
Trial Results to be Presented at Europace 2007 in Lisbon
ST. PAUL, Minn.--(BUSINESS WIRE)--June 22, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced CE Mark approval of its new
OptiSense(TM) lead, a first-of-its-kind pacing lead designed to offer
more accurate sensing in the upper chamber of the heart (right
atrium). The lead, which will be introduced at the Europace 2007
Meeting in Lisbon, Portugal, i... |
| | | 06/11/07 | St. Jude Medical to Present at William Blair & Company 27th Annual Growth Stock Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--June 11, 2007--St. Jude Medical,
Inc. (NYSE:STJ) will present at the William Blair & Company 27th
Annual Growth Stock Conference on Tuesday, June 19, 2007, in Chicago.
John C. Heinmiller, Executive Vice President and Chief Financial
Officer, will address the conference at 1:00 p.m. CT. The presentation
will be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and... |
| | | 05/21/07 | St. Jude Medical to Present at Bank of America Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--May 21, 2007--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Bank of America Health Care
Conference on Thursday, May 31, 2007, in Las Vegas. John C.
Heinmiller, Executive Vice President and Chief Financial Officer, will
address the conference at 2:40 p.m. PT. The presentation will be web
cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patien... |
| | | 05/16/07 | St. Jude Medical Announces Results of Shareholders' Vote at Annual Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--May 16, 2007--St. Jude Medical,
Inc. (NYSE:STJ) announced at its annual meeting of shareholders today
that Michael A. Rocca and Stefan K. Widensohler were elected to the
Company's Board of Directors for three-year terms.
In addition, shareholders approved the St. Jude Medical, Inc. 2007
Stock Incentive Plan and the St. Jude Medical, Inc. 2007 Employee
Stock Purchase Plan, and ratified the appointment of Ernst & Young LLP
as the Company's Independe... |
| | | 05/09/07 | St. Jude Medical Showcases New Product Offerings at Heart Rhythm Society Meeting in Denver| ST. PAUL, Minn.--(BUSINESS WIRE)--May 9, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced it will be showcasing 12 new product
offerings at the Heart Rhythm Society's 28th Annual Scientific
Sessions in Denver. These products include industry or company
"firsts," representing every aspect of cardiac rhythm management
technology:
-- Merlin(TM).net Patient Care Network (PCN) remote monitoring - An
Internet-based central repository where physicians can access
patient... |
| | | 05/09/07 | St. Jude Medical Announces FDA Approvals of Current ICD and Promote CRT-D Heart Failure Devices| First Devices Built on Company's New Consolidated Platform
ST. PAUL, Minn.--(BUSINESS WIRE)--May 9, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of its newest devices for treating patients with
potentially lethal heart arrhythmias and heart failure. The
Current(TM) ICD (implantable cardioverter defibrillator) and
Promote(TM) CRT-D (cardiac resynchronization therapy defibrillator)
are St. Jude Medical's first devices to be... |
| | | 05/09/07 | St. Jude Medical Announces FDA Approval of the OptiSense(TM) Pacing Lead| New lead allows for more sensitive sensing of signals from the upper chamber of the heartST. PAUL, Minn., May 09, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and
Drug Administration (FDA) approval of its new OptiSense(TM) lead, a
first-of-its-kind "smart" pacing lead designed to offer more accurate
sensing in the upper chamber of the heart (right atrium). The lead
incorporates a new tip design that reduces extraneous signals from the
heart's lower cha... |
| | | 05/08/07 | St. Jude Medical Announces Expanded European CE Mark to Include Therapy Cool Path Bi-Directional Irrigated Ablation Catheter; U.S. Approval for Therapy Cool Path Irrigated Ablation Catheter| ST. PAUL, Minn.--(BUSINESS WIRE)--May 8, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced expanded European CE Mark approval to
include the Therapy(TM) Cool Path(TM) irrigated ablation catheter with
bi-directional steering for use in ablation procedures to treat
abnormal heart rhythms.
This catheter is the first open-irrigated ablation catheter to
provide bi-directional steering, a feature designed to help physicians
maneuver the catheter in difficult areas of the heart and... |
| | | 05/08/07 | St. Jude Medical Announces European Approval of Company's First Wireless ICD and CRT-D Heart Failure Devices| First Devices Built on Company's New Consolidated PlatformST. PAUL, Minn., May 08, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced European CE Mark
approval of its first wireless devices to treat patients with heart
failure and with potentially lethal heart arrhythmias. The Promote(TM)
RF CRT-D (cardiac resynchronization therapy defibrillator) and
Current(TM) RF ICD (implantable cardioverter defibrillator) feature
radiofrequency (RF) telemetry for wireless communic... |
| | | 05/08/07 | St. Jude Medical Announces FDA Clearance and European Approvals for Cardiac Mapping and Navigation Software| ST. PAUL, Minn.--(BUSINESS WIRE)--May 8, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance and European CE Mark for the EnSite(TM) System Version
7 software, and European CE Mark of the EnSite Fusion(TM) Registration
Module. The new products will help physicians create more detailed
images of the heart for navigating during electrophysiology (EP)
procedures that treat complex arrhythmias.
The EnSite System provides highly det... |
| | | 05/07/07 | St. Jude Medical Announces CRM Succession Plan|
Eric S. Fain To Become President of Cardiac Rhythm Management
Division
Michael J. Coyle to Transition Leadership Role Over Next Few
Months
ST. PAUL, Minn.--(BUSINESS WIRE)--May 7, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced that Eric S. Fain will become
President of its Cardiac Rhythm Management Division (CRMD) effective
July 1, 2007, succeeding Michael J. Coyle, who will transition out of
t... |
| | | 05/03/07 | St. Jude Medical Announces U.S. And European Approvals of Zephyr Pacemaker Family of Devices|
New pacemakers save clinic time by automatically performing
follow-up tests prior to office visits, and by bringing time-saving
optimization to pacing
ST. PAUL, Minn.--(BUSINESS WIRE)--May 3, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced receipt of U.S. Food and Drug
Administration (FDA) and European CE Mark approvals of its newest
pacemaker family, and the first implants of the devices. The
Zephyr(TM) pacemaker is designed to save valuable ... |
| | | 04/25/07 | St. Jude Medical to Present at 2007 Morgan Stanley Global Healthcare Unplugged Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--April 25, 2007--St. Jude
Medical, Inc. (NYSE:STJ) will present at the 2007 Morgan Stanley
Global Healthcare Unplugged Conference on Friday, May 4, 2007, in Key
Biscayne, Fla. Daniel J. Starks, Chairman, President and Chief
Executive Officer, will address the conference at 9:30 a.m. ET. The
presentation will be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and... |
| | | 04/23/07 | St. Jude Medical to Present at Deutsche Bank - 2007 Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--April 23, 2007--St. Jude
Medical, Inc. (NYSE:STJ) will present at the Deutsche Bank - 2007
Health Care Conference on Thursday, May 3, 2007, in Washington, DC.
John C. Heinmiller, Executive Vice President and Chief Financial
Officer, will address the conference at 1:00 p.m. ET. The presentation
will be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic ... |
| | | 04/19/07 | St. Jude Medical Announces Pricing of Convertible Debt Offering| ST. PAUL, Minn.--(BUSINESS WIRE)--April 19, 2007--St. Jude
Medical, Inc. (NYSE:STJ) announced today the pricing of $1.2 billion
in aggregate principal amount of its Convertible Senior Debentures due
December 2008 in a private offering to qualified institutional buyers
pursuant to Rule 144A under the Securities Act of 1933, as amended.
The debentures will pay interest semi-annually at a rate of 1.22% per
annum. The debentures are convertible in certain circumstances into
cash up to the... |
| | | 04/19/07 | St. Jude Medical Announces Convertible Debt Offering| ST. PAUL, Minn., Apr 19, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) announced today its intention to
offer $1 billion in aggregate principal amount of Convertible Senior
Debentures due December 2008 in a private offering to qualified
institutional buyers pursuant to Rule 144A under the Securities Act of
1933, as amended. The debentures are convertible in certain
circumstances into cash up to the principal amount. Any conversion
value above the principal amount will be conver... |
| | | 04/19/07 | St. Jude Medical Reports First Quarter Results| ST. PAUL, Minn.--(BUSINESS WIRE)--April 19, 2007--St. Jude
Medical, Inc. (NYSE:STJ) today reported sales and net earnings for the
first quarter ended March 31, 2007.
First Quarter Results
The company reported net sales of $887 million in the first
quarter of 2007, an increase of 13% compared to the $784 million in
the first quarter of 2006. Favorable foreign currency translation
comparisons increased first quarter sales by approximately $18
million.
Reported net earnings... |
| | | 04/18/07 | St. Jude Medical Announces FDA Approval of Internet-Based Data Management System For Implantable Cardiac Devices| Merlin(TM).net Patient Care Network is First Cardiac Rhythm
Management Remote Monitoring System to Comply with Industry Standards
for Patient Electronic Health Records
ST. PAUL, Minn.--(BUSINESS WIRE)--April 18, 2007--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of the Merlin.net Patient Care Network,
(PCN), an Internet-based central repository for patient device data
that enables physicians and clinicians... |
| | | 04/04/07 | St. Jude Medical Announces First Quarter 2007 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--April 4, 2007--St. Jude Medical,
Inc. (NYSE:STJ) will hold its quarterly conference call to discuss
First Quarter 2007 results on April 19th at 8:30 a.m. Eastern Time
(7:30 a.m. Central Time). A news release will be issued at 7:30 a.m.
Eastern Time (6:30 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at St. Jude
Medical's web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribution N... |
| | | 03/20/07 | St. Jude Medical Announces FDA Approval of First U.S. Heart Failure Device with AF Suppression Technology| Atlas II+ HF CRT-D Helps Physicians Manage Atrial Fibrillation,
Which Commonly Accompanies Heart Failure
ST. PAUL, Minn.--(BUSINESS WIRE)--March 20, 2007--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of a new cardiac rhythm management
device designed to help physicians manage heart failure (HF) patients,
including patients who have or may develop atrial fibrillation (AF).
The Atlas(R) II+ HF CRT-D (cardiac re... |
| | | 03/12/07 | St. Jude Medical to Present at Tenth Annual Lehman Brothers' Global Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--March 12, 2007--St. Jude
Medical, Inc. (NYSE:STJ) will present at the Tenth Annual Lehman
Brothers' Global Healthcare Conference on Tuesday, March 20, 2007, in
South Beach, Florida. Daniel J. Starks, Chairman, President and Chief
Executive Officer, will address the conference at 4:45 p.m. ET. The
presentation will be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurologi... |
| | | 03/05/07 | St. Jude Medical Named FORTUNE Magazine's Most Admired Medical Products and Equipment Company| ST. PAUL, Minn., Mar 05, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced that FORTUNE
Magazine has named it one of "America's Most Admired Companies" for
2007. St. Jude Medical ranked No. 1 in the Medical Products and
Equipment Companies category.
"St. Jude Medical is delighted to be recognized yet again by one
of the most respected and influential financial publications in the
world," said Daniel J. Starks, chairman, president and CEO of St. Jude
Medical. "This ... |
| | | 02/28/07 | St. Jude Medical Announces Spinal Cord Stimulation Pilot Study for Chronic Angina| 53-year-old woman from Massachusetts becomes first patient
implanted in trial
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 28, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced the first patient implant in a pilot
study that will preliminarily evaluate if stimulating nerves near the
spinal cord will control chronic chest pain caused by angina.
A 53-year-old Massachusetts woman is the first person to receive
this investigational device, called the Gene... |
| | | 02/27/07 | St. Jude Medical Completes Milestone to Standardize Patient Medical Records|
St. Jude Medical is first cardiac rhythm management device maker
to participate in test of communications standards initiative to
improve healthcare information sharing
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 27, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced it has successfully completed the
testing process established by the IHE (Integrating the Healthcare
Enterprise), an initiative promoting the adoption of standards that
enable healthcare informa... |
| | | 02/21/07 | St. Jude Medical Receives FDA Clearance for Venture Catheter with New Delivery Platform| Catheter Provides Exceptional Control in Treating Hard-to-Reach
Areas of Coronary Anatomy
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 21, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance for the Venture(TM) Wire Control Catheter on a rapid
exchange delivery platform, a delivery design that accommodates
shorter guidewires and may result in quicker, easier coronary
procedures.
In the United States, more ... |
| | | 02/15/07 | St. Jude Medical Announces FDA Clearance of Spinal Cord Stimulation Leads for Patients with Low Back Pain| Tripole 16C helps physicians customize care with 16 independent
electrodes
ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 15, 2007--St. Jude Medical,
Inc. (NYSE:STJ), today announced U.S. Food and Drug Administration
(FDA) clearance of two spinal cord stimulation tripolar paddle leads
for use with the Renew(R) Neurostimulation System. With three columns
of electrodes, these leads allow physicians more programming options
to address complex pain patterns.
... |
| | | 02/02/07 | St. Jude Medical Announces 2007 Analyst Meeting| MINNEAPOLIS, Feb 02, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) will hold its 2007 Analyst
Meeting on Friday, February 9, 2007, from 7:30 a.m.- 3:30 p.m. Eastern
time (6:30 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribution Network to both institutional and individual investors.
Individual investors can listen to the call through CCBN's indivi... |
| | | 01/31/07 | Journal of Cardiovascular Electrophysiology Publishes Study on Time-Saving Approach to Optimizing Timing for Heart Failure and ICD Devices| St. Jude Medical's QuickOpt Feature Provides Reliable, Simpler
Alternative to Traditional Optimization
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 31, 2007--Clinical trial
results showing the effectiveness of a new approach for optimizing
cardiac devices will be published in the peer-reviewed Journal of
Cardiovascular Electrophysiology (JCE) in February 2007. The study
found that St. Jude Medical's (NYSE:STJ) QuickOpt(TM) Timing Cycle
Optimization is equivalent to tradi... |
| | | 01/25/07 | St. Jude Medical Reports Fourth Quarter and Full-Year 2006 Results| Announces $1 Billion Stock Repurchase Plan
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 25, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today reported sales and net earnings for the fourth
quarter and full-year ended December 30, 2006. The company also
announced that its Board of Directors has authorized a share
repurchase program under which the company is authorized to repurchase
up to $1 billion in St. Jude Medical common stock.
Fourth Quarter and Full-Year Results
The company r... |
| | | 01/17/07 | Advanced Neuromodulation Systems Receives European Approval for Rapid Programmer(R) 3.0 Clinician Programming Platform| Approval Coincides with Launch of Enhanced Rechargeable Spinal
Cord Stimulation Device
PLANO, Texas--(BUSINESS WIRE)--Jan. 17, 2007--Advanced
Neuromodulation Systems (ANS), the neuromodulation business of St.
Jude Medical, Inc. (NYSE:STJ), today announced European CE Mark
approval for its newest clinician programming platform, Rapid
Programmer 3.0 for spinal cord stimulation (SCS), an advanced therapy
for managing chronic pain.
Coinciding with this app... |
| | | 01/11/07 | St. Jude Medical Announces FDA Clearance and European Approval of New Electrophysiology Products| Atrial Fibrillation Symposium to Showcase Company's Expanded
Product Offering
ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 11, 2007--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance and European CE Mark approval of the Reflexion
Spiral(TM) Variable Radius Mapping Catheter and a faster, smaller
EnSite(R) System workstation computer.
St. Jude Medical will feature these products for the first time at
the Bosto... |
| | | 01/10/07 | St. Jude Medical Announces Fourth Quarter 2006 Earnings Conference Call| MINNEAPOLIS, Jan 10, 2007 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE: STJ) will hold its quarterly
conference call to discuss the Fourth Quarter 2006 earnings on January
25th at 8:30 a.m. Eastern Time (7:30 a.m. Central Time). The news
release will be issued at 7:30 a.m. Eastern Time (6:30 a.m. Central
Time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribution Network to bo... |
| | | 01/08/07 | St. Jude Medical Announces Preliminary Fourth Quarter 2006 Results| ST PAUL, Minn.--(BUSINESS WIRE)--Jan. 8, 2007--St. Jude Medical,
Inc., (NYSE:STJ) today announced preliminary results for the fourth
quarter ended December 31, 2006.
The Company will report net sales of approximately $864 million
for the fourth quarter of 2006, an increase of more than 9% compared
to the fourth quarter of 2005 and approximately $20 million above
current analysts' consensus revenue estimates. The Company also
expects consolidated fourth quarter earnings per share t... |
| | | 01/04/07 | St. Jude Medical to Present at 25th Annual JP Morgan Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 4, 2007--St. Jude Medical,
Inc. (NYSE:STJ) will present at the 25th Annual JP Morgan Healthcare
Conference on Monday, January 8, 2007, in San Francisco. Daniel J.
Starks, Chairman, President and Chief Executive Officer, will address
the conference at 3:00 p.m. PT. The presentation will be web cast live
at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain pat... |
| | | 11/28/06 | St. Jude Medical Announces FDA Approval of Optim Lead Insulation for Cardiac Rhythm Management Therapy| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 28, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of an innovative insulation material for cardiac leads
used with pacemakers and implantable cardioverter defibrillators
(ICDs). Optim(TM) lead insulation is the first silicone-polyurethane
co-polymer material created specifically for cardiac lead use.
The new Optim insulation is designed for long-term reliability,
while providing physi... |
| | | 11/21/06 | St. Jude Medical to Present at Piper Jaffray Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 21, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Piper Jaffray Health Care
Conference on Wednesday, November 29, 2006, in New York. John C.
Heinmiller, executive vice president and chief financial officer, will
address the conference at 8:30 a.m. ET. The presentation will be web
cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain pa... |
| | | 11/15/06 | Results of Clinical Trial Demonstrate That a New, Non-invasive Test is Comparable to Invasive Tests in Identifying Patients Who Could Benefit from ICDs| Trial Results Presented Today at American Heart Association 2006 Scientific SessionsCHICAGO, Nov 15, 2006 (BUSINESS WIRE) -- New clinical trial results from the Alternans Before Cardioverter
Defibrillator (ABCD) trial were presented today at the American Heart
Association's 2006 Scientific Sessions conference in Chicago. The
study found that a non-invasive test that uses computer technology to
predict a patient's risk for sudden cardiac death has proven itself
comparable to an invasive and ... |
| | | 11/07/06 | St. Jude Medical Announces FDA Approval of New ICD Software for the Merlin(TM) Patient Care System| Software Provides Fast and Simple Programming of ICD Devices
ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 7, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of its new tachycardia software for the Merlin(TM)
Patient Care System, a state-of-the-art computer used to program and
interrogate cardiac rhythm management devices like pacemakers and
implantable cardioverter defibrillators (ICDs).
This software upgrade, which will be la... |
| | | 11/06/06 | Results from St. Jude Medical's Study of Microvolt T-Wave Alternans to be Presented at the 2006 American Heart Association Scientific Sessions| ST. PAUL, Minn., and BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 6,
2006--St. Jude Medical, Inc. (NYSE:STJ) and Cambridge Heart, Inc.
(OTCBB:CAMH) today announced that the findings of the Alternans Before
Cardioverter Defibrillator (ABCD) clinical study will be presented at
the American Heart Association (AHA) 2006 Annual Scientific Sessions
in Chicago, Ill.
The ABCD clinical study results will be presented at the AHA's
Late Breaking Clinical Trials sessions on Wednesday, Nov. 15.
... |
| | | 10/18/06 | St. Jude Medical Reports Third Quarter Sales and Earnings| ST PAUL, Minn.--(BUSINESS WIRE)--Oct. 18, 2006--St. Jude Medical,
Inc., (NYSE:STJ) today reported results for the third quarter ended
September 30, 2006. The Company reported net sales of $821 million, an
increase of 11% compared to the $738 million reported in the third
quarter of 2005. Favorable foreign currency translation comparisons
increased third quarter sales by about $7 million.
Reported net earnings for the third quarter of 2006 were $116
million, or $0.32 per diluted sh... |
| | | 10/16/06 | St. Jude Medical Appoints Dr. Mark D. Carlson as Chief Medical Officer and Senior Vice President, Clinical Affairs, for CRM Division| ST PAUL, Minn.--(BUSINESS WIRE)--Oct. 16, 2006--St. Jude Medical,
Inc., (NYSE:STJ) announced today that Mark D. Carlson, M.D., has been
appointed chief medical officer and senior vice president, Clinical
Affairs, of St. Jude Medical's Cardiac Rhythm Management (CRM)
Division, effective Nov. 13.
With more than 25 years of experience in patient care, public
policy development and cardiac research, Dr. Carlson is widely
considered one of the foremost experts in cardiology and cardiac... |
| | | 10/13/06 | St. Jude Medical Develops Software Upgrade to Remedy Low-Frequency Anomaly for Certain Programmers| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 13, 2006--St. Jude Medical,
Inc., (NYSE:STJ) announced today that it has developed a software
upgrade that fully remedies a low-frequency anomaly in the software
used in the APS III Model 3510 and Merlin PCS Model 3650 programmers.
In particular, when these tabletop programmers are used with
certain models of Identity pacemakers, the anomaly in the programmer's
software may lead to incorrect reporting of battery voltage, expected
battery long... |
| | | 10/04/06 | St. Jude Medical Announces European Approval of Atlas II ICD and Atlas II Heart Failure Devices| Business Editors/Health Writers
ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 4, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced European CE Mark approval of its
newest high-powered devices for treatment of patients with potentially
lethal heart arrhythmias and heart failure (HF).
The Atlas(TM) II implantable cardioverter defibrillator (ICD) and
the Atlas(TM) II HF cardiac resynchronization therapy defibrillator
(CRT-D) devices include advanced features that provide more tail... |
| | | 10/03/06 | Advanced Neuromodulation Systems Receives Australian Regulatory and Reimbursement Approval for Rechargeable Chronic Pain System| Sydney patients among first to be implanted with new pain devicePLANO, Texas & SYDNEY, Australia, Oct 03, 2006 (BUSINESS WIRE) -- Advanced Neuromodulation Systems (ANS), the neuromodulation
business of St. Jude Medical, Inc. (NYSE:STJ), today announced
Australian Therapeutic Goods Administration (TGA) regulatory approval
for its Eon(TM) Rechargeable Neurostimulation System. In Australia,
the Eon system is fully reimbursable via the private health system.
Patients at the Pain Management Re... |
| | | 09/28/06 | St. Jude Medical Comments on Heart Rhythm Society Recommendations on Device Performance Policies and Guidelines| Business Editors/Health/Medical Writers
ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 28, 2006--St. Jude
Medical, Inc., (NYSE:STJ) today commended the Heart Rhythm Society
(HRS) for engaging industry stakeholders, including physicians,
patient groups and the U.S. Food and Drug Administration, in
developing its recommendations on device performance policies and
guidelines as announced earlier today.
"We recognize the important role that communications can play in
helping our stakeho... |
| | | 09/26/06 | St. Jude Medical Announces Third Quarter 2006 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--Sept. 26, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will hold its quarterly conference call to discuss the
Third Quarter 2006 earnings on October 18th at 8:30 a.m. Eastern Time
(7:30 a.m. Central Time). The news release will be issued at 7:30 a.m.
Eastern Time (6:30 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribution Netw... |
| | | 09/19/06 | St. Jude Medical Announces FDA and European CE Mark Approvals of Tendril ST(R) Pacemaker Lead; Thin, Highly Visible Lead Designed for Easier Implants and Reduced Trauma to Heart Tissue| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 19, 2006--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) and European CE Mark approvals of the new
Tendril(R) ST model 1788 lead, a new pacemaker lead whose thin
structure is designed for easier implantation.
The Tendril ST lead is one of the thinnest pacing leads on the
market, using low-profile, flat-wire technology to reduce the size of
the outer coil and lead body. The thin diameter makes it eas... |
| | | 09/15/06 | St. Jude Medical to Present at Bank of America 36th Annual Investment Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 15, 2006--St. Jude
Medical, Inc. (NYSE:STJ) will present at the Bank of America 36th
Annual Investment Conference on September 19, 2006, in San Francisco,
CA. John C. Heinmiller, executive vice president and chief financial
officer, will address the conference at 8:00 a.m. PT. The presentation
will be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological an... |
| | | 09/07/06 | St. Jude Medical to Present at Bear Stearns 19th Annual Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 7, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Bear Stearns 19th Annual
Healthcare Conference on September 12, 2006, in New York. John C.
Heinmiller, executive vice president and chief financial officer, will
address the conference at 10:00 a.m. ET. The presentation will be web
cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pa... |
| | | 08/28/06 | St. Jude Medical to Create New Cardiovascular Division; Combination of Cardiac Surgery and Cardiology Divisions Expected to Accelerate Product Development and Enhance Operating Efficiencies| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 28, 2006--St. Jude Medical,
Inc. (NYSE:STJ) announced today that it is combining its Cardiac
Surgery and Cardiology divisions to create a new Cardiovascular
Division, effective January 1, 2007.
"This strategic reorganization is another example of St. Jude
Medical's commitment to continuous improvement and to focusing on the
needs of our customers," said Daniel J. Starks, Chairman, President
and Chief Executive Officer of St. Jude Medical. "... |
| | | 08/22/06 | St. Jude Medical Announces FDA Approval and Launch of QuickOpt(TM) Timing Cycle Optimization for Heart Failure and ICD Patients; Innovative Feature Addresses 'Non-Optimization' of Device Patients| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 22, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval and launch of QuickOpt(TM) Timing Cycle Optimization.
This new programmer feature is designed to help physicians improve
patient outcomes for people with cardiac resynchronization therapy
defibrillator (CRT-D) devices and traditional implantable cardioverter
defibrillators (ICDs) by providing a programmer-based optimization
method that pro... |
| | | 08/04/06 | Company Profile for St. Jude Medical| --(BUSINESS WIRE)--St. Jude Medical is dedicated to making life
better for cardiac, neurological and chronic pain patients worldwide
through excellence in medical device technology and services. The
Company has five major focus areas that include: cardiac rhythm
management, atrial fibrillation, cardiac surgery, cardiology and
neuromodulation. Headquartered in St. Paul, Minn., the Company employs
approximately 10,000 people worldwide. For more information, please
visit www.sjm.com.
... |
| | | 08/04/06 | Newly Published Guidelines for Treatment of Heart Valve Disease Lower Recommended Age for Tissue Valve Recipients| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 4, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today recognized the significance of new published
guidelines for the diagnosis and treatment of heart valve disease,
developed by the American College of Cardiology (ACC) and the American
Heart Association (AHA). A summary of the guidelines was published in
the Aug. 1, 2006, issue of the Journal of the American College of
Cardiology and Circulation.
The new recommendations offer the first comprehe... |
| | | 07/31/06 | St. Jude Medical and Boston Scientific Settle Patent Litigation| ST. PAUL, Minn. & NATICK, Mass., Jul 31, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) and Boston Scientific
Corporation (NYSE:BSX) today announced that they have entered into an
agreement that resolves four previously disclosed patent litigation
matters pending between the companies and certain of their affiliates.
Under the settlement, St. Jude Medical and Boston Scientific have
also agreed to limit how two previously disclosed patent cases, though
not resolved, will be p... |
| | | 07/19/06 | St. Jude Medical Reports Second Quarter Sales and Earnings| ST. PAUL, Minn.--(BUSINESS WIRE)--July 19, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today reported results for the second quarter ended
June 30, 2006. The Company reported net sales of $833 million, an
increase of 15% compared to the $724 million reported in the second
quarter of 2005. Unfavorable foreign currency translation comparisons
decreased second quarter sales by about $6 million.
Reported net earnings for the second quarter of 2006 were $141
million, or $0.38 per diluted... |
| | | 07/18/06 | St. Jude Medical Announces FDA Approval of Atlas II ICD and Atlas II Heart Failure Devices; Powerful, High-Energy Devices Are Designed to Help Patients Whose Hearts Are Especially Difficult to Defibrillate| ST. PAUL, Minn., Jul 18, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S.
Food and Drug Administration (FDA) approval of new, powerful devices
for treating patients with potentially lethal heart arrhythmias and
heart failure.
The Atlas(R) II ICD (implantable cardioverter defibrillator) and
the Atlas(R) II HF CRT-D (cardiac resynchronization therapy
defibrillator) devices are capable of delivering unsurpassed energy,
giving added security to patients whose hea... |
| | | 07/07/06 | St. Jude Medical Announces Second Quarter 2006 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--July 7, 2006--St. Jude Medical, Inc.
(NYSE:STJ) will hold its quarterly conference call to discuss the
Second Quarter 2006 earnings on July 19th at 8:30 a.m. Eastern Time
(7:30 a.m. Central Time). The news release will be issued at 7:30 a.m.
Eastern Time (6:30 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribution Netw... |
| | | 07/06/06 | St. Jude Medical Announces Agreement With LUMEDX To Manage Cardiovascular Patient Data| ST. PAUL, Minn.--(BUSINESS WIRE)--July 6, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced a joint marketing and development
agreement with LUMEDX to integrate and manage cardiovascular patient
data. LUMEDX is a leading cardiovascular information systems provider
with more than 350 heart center customers worldwide.
Under the agreement, data from St. Jude Medical's recently
approved Merlin(TM) Patient Care System will automatically feed into
the LUMEDX Apollo Advance(TM) c... |
| | | 06/23/06 | St. Jude Medical to Present at William Blair's 26th Annual Growth Stock Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--June 23, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the William Blair 26th Annual Growth
Stock Conference on June 27, 2006, in Chicago, Ill. John C.
Heinmiller, executive vice president and chief financial officer
(CFO), will address the conference at 4:20 p.m. CT. The presentation
will be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chr... |
| | | 06/16/06 | Clinical Trial Shows Device Optimizes Cardiac Resynchronization Therapy in Less Than Two Minutes; St. Jude Medical Announces QuickOpt Optimization Clinical Trial Results and European Regulatory Approvals at Cardiostim 2006| ST. PAUL, Minn., Jun 16, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced the
clinical trial results, receipt of European CE Mark approval and
European market launch of its QuickOpt(TM) Timing Cycle Optimization.
The trial results were presented by James G. Porterfield, M.D.,
principal investigator in the trial conducted under a U.S. Food and
Drug Administration (FDA) Investigational Device Exemption (IDE),
during a late-breaking clinical trial session at Cardiosti... |
| | | 06/14/06 | St. Jude Medical Announces European CE Mark of New Products at International Cardiac Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--June 14, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced European CE Mark approval for two new
electrophysiology (EP) products - the Therapy(TM) Cool Path(TM)
all-braided ablation catheter and the IBI-1400-CV Internal
Cardioversion system.
The announcement was made at Cardiostim 2006, an international
bi-annual meeting of cardiac specialists, which began June 14 in Nice,
France.
St. Jude Medical will present results from its Quick... |
| | | 06/13/06 | St. Jude Medical Announces European Approval of Epic II ICD and Epic II Heart Failure Devices; First European Implant of Epic II ICD in Switzerland| ST. PAUL, Minn.--(BUSINESS WIRE)--June 13, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced European CE Mark approval of its
newest devices for treating patients with potentially lethal heart
arrhythmias and heart failure.
The Epic(TM) II ICD (implantable cardioverter defibrillator) and
the Epic(TM) II HF CRT-D (cardiac resynchronization therapy
defibrillator) feature faster device data transmission to speed
patient follow-up exams and a "patient notifier" that gently vib... |
| | | 06/09/06 | St. Jude Medical to Present at the Goldman Sachs Twenty-Seventh Annual Global Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--June 9, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Goldman Sachs Twenty-Seventh
Annual Global Healthcare Conference on June 13, 2006, in Dana Point,
Calif. John C. Heinmiller, Executive Vice President and CFO, will
address the conference at 3:20 p.m. PT. The presentation will be web
cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pa... |
| | | 06/01/06 | St. Jude Medical Announces Japanese Approvals of EnSite System; Computer-based Visualization and Navigation Tool Used with Heart Rhythm Patients| ST. PAUL, Minn.--(BUSINESS WIRE)--June 1, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced regulatory and reimbursement approvals
from Japan's Ministry of Health, Labor and Welfare for the EnSite(R)
System in Japan. The EnSite System is a computer-based visualization
and navigation tool used by physicians when treating patients with
irregular heartbeats.
The EnSite System allows electrophysiologists (physicians who
practice a sub-specialty of cardiology) to create compute... |
| | | 05/31/06 | St. Jude Medical to Present at Sanford Bernstein's Twenty-Second Annual Strategic Decisions Conference| ST. PAUL, Minn., May 31, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will present at the
Sanford Bernstein Twenty-Second Annual Strategic Decisions Conference
on June 2, 2006, in New York. Daniel J. Starks, Chairman, President
and Chief Executive Officer, will address the conference at 9:00 a.m.
ET. The presentation will be web cast live at www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain pat... |
| | | 05/31/06 | IBM Collaborates With St. Jude Medical on New State-of-the-Art Cardiac Patient Care System| Breakthrough Technology Designed to Help Physicians More Efficiently Monitor and Program ICDs and PacemakersARMONK, NY, May 31, 2006 (MARKET WIRE via COMTEX News Network) -- IBM today announced it has collaborated with St. Jude Medical, Inc.
(NYSE: STJ) to produce the St. Jude Medical Merlin(TM) Patient Care
System, a portable system that programs St. Jude Medical's
implantable cardioverter defibrillators (ICDs) and pacemakers. IBM
provided resources, industry experience, and consulting to ... |
| | | 05/17/06 | St. Jude Medical Announces FDA Approval, FDA Clearance and European CE Mark of New Electrophysiology Products; Heart Rhythm Society Meeting to Showcase Strength and Breadth of Product Offering| ST. PAUL, Minn.--(BUSINESS WIRE)--May 17, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of its Safire(TM) Ablation Catheter, and FDA clearance
and European CE Mark for its Inquiry(TM) Optima(TM) PLUS Steerable
Diagnostic Catheter.
St. Jude Medical made the announcement at the Heart Rhythm
Society's 27th Annual Scientific Sessions in Boston, where these
products will be featured for the first time.
The Safire cathe... |
| | | 05/16/06 | St. Jude Medical Highlights New Arrhythmia Devices at Heart Rhythm 2006 Meeting| ST. PAUL, Minn., May 16, 2006 (BUSINESS WIRE) -- St. Jude Medical will showcase a broad array of new
cardiac rhythm management (CRM) products at the Heart Rhythm Society's
27th Annual Scientific Sessions, an international meeting of
clinicians who treat patients with heart rhythm disorders, including
heart failure.
In recent weeks, St. Jude Medical received U.S. Food and Drug
Administration (FDA) approvals for several significant CRM devices. In
April 2006, the company received FDA approv... |
| | | 05/16/06 | GE Healthcare and St. Jude Medical Announce Collaboration Agreement to Help Fight Heart Disease and Stroke; Collaboration Agreement Brings Together Real-Time Imaging Technologies to Help Physicians Combat Disease | WAUKESHA, Wis. & ST. PAUL, Minn.--(BUSINESS WIRE)--May 16, 2006--GE Healthcare (NYSE:GE) and St. Jude Medical, Inc. (NYSE:STJ) today announced a significant development and collaboration agreement that is intended to bring an integrated imaging and monitoring capability to cardiac catheterization labs around the world. Under terms of the agreement, GE and St. Jude Medical will develop a state-of-the-art cardiovascular ultrasound imaging system with fully integrated intracardiac echocardiography ... |
| | | 05/16/06 | St. Jude Medical Announces FDA Approval of Epic II ICD and Epic II Heart Failure Devices| ST. PAUL, Minn.--(BUSINESS WIRE)--May 16, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval of its newest devices for treating patients with
potentially lethal heart arrhythmias and heart failure.
The Epic(R) II ICD (implantable cardioverter defibrillator) and
the Epic(R) II HF CRT-D (cardiac resynchronization therapy
defibrillator) devices feature significantly enhanced telemetry speed
for faster device communications and a "... |
| | | 05/15/06 | St. Jude Medical Announces FDA Clearance of EnSite(R) System 6 Software for Cardiac Mapping and Navigation| ST. PAUL, Minn.--(BUSINESS WIRE)--May 15, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) clearance of the EnSite(R) System Version 6 software, which
provides improved clinical capabilities for cardiac mapping and
navigation during electrophysiology (EP) procedures.
EnSite System Version 6 is designed to provide highly detailed,
three-dimensional (3-D) cardiac models at the time of an EP procedure.
Physicians create the 3-D model i... |
| | | 05/11/06 | St. Jude Medical to Present at the Bank of America Health Care Conference 2006| ST. PAUL, Minn.--(BUSINESS WIRE)--May 11, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Bank of America Health Care
Conference 2006 on May 16, 2006, in Las Vegas. Daniel J. Starks,
Chairman, President and Chief Executive Officer, will address the
conference at 8:00 a.m. PT. The presentation will be web cast live at
www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients world... |
| | | 05/10/06 | St. Jude Medical Announces Results of Shareholders' Vote at Annual Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--May 10, 2006--St. Jude Medical,
Inc. (NYSE:STJ) announced at its annual meeting of shareholders today
that John W. Brown and Daniel J. Starks were elected to the Company's
Board of Directors for three-year terms.
In addition, shareholders approved the St. Jude Medical, Inc.,
2006 Stock Plan and ratified the appointment of Ernst and Young LLP as
the Company's Independent Registered Public Accountants.
About St. Jude Medical
St. Jude ... |
| | | 05/08/06 | Advanced Neuromodulation Systems Receives European CE Mark Clearance for Eon Rechargeable Neurostimulation System; First Patient Implant Completed in Europe| PLANO, Texas--(BUSINESS WIRE)--May 8, 2006--Advanced
Neuromodulation Systems (ANS), the neuromodulation business of St.
Jude Medical, Inc. (NYSE:STJ), today announced it has received
European CE Mark clearance for its Eon(TM) Rechargeable
Neurostimulation System, and announced the first European patient
implant of the Eon System.
The Eon Neurostimulation System helps patients manage chronic,
intractable pain of the trunk and limbs, including pain associated
with failed back sur... |
| | | 05/02/06 | St. Jude Medical Announces Regulatory Approvals and Market Launch of the QuickSite XL Lead| ST. PAUL, Minn., May 02, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S.
Food and Drug Administration (FDA) approval, receipt of European CE
Mark clearance and market launch of the QuickSite(R) XL bipolar,
left-heart lead to treat heart failure patients.
The QuickSite XL lead is used in cardiac resynchronization therapy
(CRT) procedures for heart failure patients with average to large size
veins. The lead's heightened S-shape is designed to provide stability
... |
| | | 05/01/06 | St. Jude Medical to Present at the Morgan Stanley Global Healthcare Unplugged Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--May 1, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Morgan Stanley Global Healthcare
Unplugged Conference on May 4, 2006, in Miami. John Heinmiller,
Executive Vice President and Chief Financial Officer, will address the
conference at 9:30 a.m. EST. The presentation will be web cast live at
www.sjm.com.
About St. Jude Medical
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patie... |
| | | 04/28/06 | St. Jude Medical To Highlight Its Cardiac Surgery Portfolio At American Association For Thoracic Surgery| ST. PAUL, Minn., Apr 28, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will demonstrate its
cardiac surgery portfolio including valve replacement, valve repair
and advanced beating-heart cardiac tissue ablation technologies at the
annual meeting of the American Association for Thoracic Surgery (AATS)
in Philadelphia on April 30-May 2, 2006.
St. Jude Medical will sponsor a symposium, "Patient-Focused Trends
for Combined Therapy," moderated by renowned cardiac surgeon, Richard
S... |
| | | 04/19/06 | St. Jude Medical Reports First Quarter Results and Announces Plans to Expand U.S. Sales Organization; Board of Directors Authorizes $700 Million Share Repurchase Program| ST. PAUL, Minn.--(BUSINESS WIRE)--April 19, 2006--St. Jude
Medical, Inc. (NYSE:STJ) today reported sales and earnings results for
the first quarter ended March 31, 2006, and announced an expansion of
its selling organization in the United States. The Company also
announced that its Board of Directors has authorized a new share
repurchase program under which the Company may repurchase up to $700
million in St. Jude Medical common stock.
First Quarter Results
The Company re... |
| | | 04/18/06 | FDA Approves St. Jude Medical's New Heart Failure Lead Delivery System| ST. PAUL, Minn.--(BUSINESS WIRE)--April 18, 2006--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration (FDA) approval of the Cardiac Positioning System
(CPS(TM)) family of lead delivery tools for heart failure.
The Cardiac Positioning System is designed to give physicians
greater control and precision when implanting cardiac
resynchronization therapy (CRT) devices (defibrillators or pacemakers)
in heart failure patients. The system especially helps... |
| | | 04/18/06 | St. Jude Medical Announces First Implant in Its Migraine Headache Study; U.S. Clinical Trial to Explore Link between Common Heart Defect and Migraine Headaches| ST. PAUL, Minn.--(BUSINESS WIRE)--April 18, 2006--St. Jude
Medical, Inc. (NYSE:STJ) today announced the implant of the first
patient in its ESCAPE (Effect of Septal Closure of Atrial PFO on
Events of Migraine with Premere(TM)) migraine trial.
The first implanted patient, a 53-year-old woman from Va., is one
of approximately 500 patients who are expected to participate in the
study. The trial will explore the link between a common heart defect,
called patent foramen ovale (PFO), ... |
| | | 04/17/06 | St. Jude Medical Announces Time Change for 1st Quarter 2006 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--April 17, 2006--St. Jude Medical
(NYSE:STJ) will release full first quarter 2006 operating results on
Wednesday, April 19, 2006. A conference call to discuss the quarter
has now been scheduled for 8:30 a.m. ET (7:30 a.m. CT). Please note
that the time of the conference call has been moved up by 30 minutes.
The press release will be issued at approximately 7:30 a.m. ET (6:30
am CT). A copy of the release will be emailed to you simultaneously.
Please call 6... |
| | | 04/17/06 | St. Jude Medical Announces FDA Approval and U.S. Market Launch of the Merlin Patient Care System; New Programmer Brings 21st Century Advances to Patient Follow-Ups| ST. PAUL, Minn., Apr 17, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U.S.
Food and Drug Administration (FDA) approval and market launch of its
Merlin(TM) Patient Care System, a universal programmer for implantable
cardioverter defibrillators (ICDs) and pacemakers. The system is
designed to help physicians more efficiently conduct tests, analyze
therapeutic and diagnostic data, and program implanted devices for
optimal patient care.
The system, which supports ... |
| | | 04/10/06 | St. Jude Medical Announces Regulatory Approvals and Market Launch of the World's Thinnest ICD Lead| ST. PAUL, Minn.--(BUSINESS WIRE)--April 10, 2006--St. Jude
Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug
Administration regulatory approval and market launch of the Riata(R)
ST lead, the world's thinnest implantable cardioverter defibrillator
(ICD) lead. The thin size is designed to make navigation easier
through difficult anatomy in cardiac patients, enabling physicians to
more precisely place leads, which is critical for successful ICD
therapy.
"The Riata ST lea... |
| | | 04/05/06 | St. Jude Medical Announces 1st Quarter 2006 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--April 5, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will hold its quarterly conference call to discuss the
1st quarter 2006 earnings Wednesday, April 19, 2006, at 9:00 a.m.
Eastern Time (8:00 a.m. Central Time). The news release will be issued
at 8:00 a.m. Eastern Time (7:00 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distr... |
| | | 04/04/06 | St. Jude Medical Announces Preliminary First Quarter Results| ST. PAUL, Minn., Apr 04, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced
preliminary results for the first quarter ended March 31, 2006.
The Company expects to report net sales of approximately $784
million in the first quarter of 2006, an increase of 18% compared to
the first quarter of 2005. The Company had previously forecasted net
sales in the $799 million to $839 million range. The Company also
expects consolidated first quarter earnings per share to be in th... |
| | | 03/20/06 | St. Jude Medical Announces First Canadian Implant of St. Jude Medical Rigid Saddle Ring| ST. PAUL, Minn.--(BUSINESS WIRE)--March 20, 2006--St. Jude
Medical, Inc. (NYSE:STJ) announced today the first Canadian implant of
the St. Jude Medical Rigid Saddle Ring with EZ(TM) Suture Cuff, a
device used for mitral heart valve repair procedures.
Dr. Nicolas Noiseux, from Hotel-Dieu, Montreal Hospital, Montreal,
Quebec, performed the implant on a patient with moderate to severe
mitral valve regurgitation, a condition where the mitral valve does
not close properly, allowing bloo... |
| | | 03/17/06 | St. Jude Medical Launches New Vascular Closure Device; Angio-Seal(TM) VIP Effectively Seals Arteries in Both Diagnostic and Interventional Procedures| ST. PAUL, Minn., Mar 17, 2006 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced U. S.
Food and Drug Administration (FDA) approval and launch of its next
generation vascular closure device, the Angio-Seal(TM) VIP.
The new device, which is approved for both diagnostic and
interventional procedures, gives physicians an improved method for
sealing arterial catheterization access sites. Because the new device
provides more coverage on the artery surface than previous devices,... |
| | | 03/02/06 | First Patient Enrolled in St. Jude Medical's Migraine Headache Study; Clinical Trial to Explore Link between Common Heart Defect and Migraine Headaches| ST. PAUL, Minn.--(BUSINESS WIRE)--March 2, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced the enrollment of the first patient in
its ESCAPE (Effect of Septal Closure of Atrial PFO on Events of
Migraine with Premere(TM)) migraine trial.
The first patient, a Virginia woman, will be one of over 500
patients to participate in the study, which received approval from the
U.S. Food and Drug Administration (FDA) for an Investigational Device
Exemption (IDE) in December 2005.
... |
| | | 03/01/06 | St. Jude Medical to Present at the Ninth Annual Lehman Brothers' Global Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--March 1, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Ninth Annual Lehman Brothers'
Global Healthcare Conference on March 9, 2006, in South Beach,
Florida. Dan Starks, Chairman, President and Chief Executive Officer
will address the conference at 4:45 p.m. ET. The presentation will be
web cast live at www.sjm.com.
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients worldwide thro... |
| | | 03/01/06 | St. Jude Medical to Present at the SG Cowen Health Care Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--March 1, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the SG Cowen Health Care Conference on
March 9, 2006, in Boston, Massachusetts. John Heinmiller, Executive
Vice President and Chief Financial Officer will address the conference
at 9:40 ET. The presentation will be web cast live at www.sjm.com.
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients worldwide through excellence in
med... |
| | | 02/28/06 | St. Jude Medical to Present at the Fifth Annual JMP Securities Research Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 28, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Fifth Annual JMP Securities
Research Conference on March 7, 2006, in San Francisco, California.
Michael Coyle, President, Cardiac Rhythm Management Division, will
address the conference at 1:30 p.m. PT. The presentation will be web
cast live at www.sjm.com.
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients worldwide through ... |
| | | 02/27/06 | ANS Unveils Rapid Programmer 3.0 at American Academy of Pain Medicine Conference; New Compact Neurostimulation Programming Platform Provides Easy-to-Use Interface, Enhanced Graphics, and Significant Programming Advances | PLANO, Texas--(BUSINESS WIRE)--Feb. 27, 2006--Advanced Neuromodulation Systems (ANS), the Neuromodulation business of St. Jude Medical, Inc. (NYSE:STJ), today announced its newest programming platform, Rapid Programmer(R) 3.0, for the management of spinal cord stimulation, a therapy used for treating chronic pain of the trunk and limbs. Introduced at the 22nd American Academy of Pain Medicine (AAPM) annual meeting in San Diego, California, this platform delivers advanced programming features, in... |
| | | 02/22/06 | St. Jude Medical to Present at the Citigroup Investment Research Global Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 22, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Citigroup Investment Research
Global Healthcare Conference on February 28, 2006, in Washington, DC.
John Heinmiller, Executive Vice President and Chief Financial Officer,
will address the conference at 11:30 a.m. EST. The presentation will
be web cast live at www.sjm.com.
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients wor... |
| | | 02/16/06 | The Larry King Cardiac Foundation Fundraising Gala Underwritten by St. Jude Medical, Inc.; Support Allows for Complete Patient Care to Save a Heart a Day| WASHINGTON, Feb 16, 2006 (BUSINESS WIRE) -- The Larry King Cardiac Foundation (LKCF) proudly
announces an underwriting donation from St. Jude Medical, Inc.
(NYSE:STJ) which will offer complete support of the Washington, DC
fundraising gala, An Evening with Larry King and Friends on March 24,
2006. It will be held at The Ritz-Carlton, Washington, DC.
The funds provided by St. Jude Medical will actively support the
ambitious mission of LKCF to Save a Heart a Day by allowing all
proceeds rai... |
| | | 02/07/06 | St. Jude Medical Announces 2006 Analyst Meeting| MINNEAPOLIS--(BUSINESS WIRE)--Feb. 7, 2006--St. Jude Medical, Inc.
(NYSE:STJ) will hold its 2006 Analyst Meeting on Friday, February 10,
2006, from 8:00 a.m.- 3:00 p.m. Eastern time (7:00 a.m. Central Time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distribution Network to both institutional and individual investors.
Individual investors can listen to the call through ... |
| | | 02/07/06 | St. Jude Medical Announces U.S. FDA Approval for Company's Newest Pacemakers; Victory Pacemaker Family Launched Immediately in U.S. and Europe| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 7, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval and market launch of its newest platform of pacemakers,
the Victory(R) family of devices. The product will be immediately
available in the United States and Europe. The product family received
a European CE Mark late last year.
Among the clinically-important features included in Victory(R)
pacemakers are optimized settings designed to... |
| | | 01/26/06 | St. Jude Medical to Focus on Future of Cardiac Surgery and Surgical Ablation at Annual Meeting of the Society of Thoracic Surgeons| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 26, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will demonstrate its focus on the future of cardiac
surgery--including new valve replacement and repair products and
advanced beating-heart cardiac tissue ablation technology--at the
upcoming annual meeting of the Society of Thoracic Surgeons (STS),
January 29-31, 2006, in Chicago.
At the meeting St. Jude Medical will showcase the SJM Biocor(R)
and SJM Biocor(R) Supra stented tissue valves, which ... |
| | | 01/25/06 | St. Jude Medical Reports Fourth Quarter and Full-Year 2005 Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 25, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today reported sales and earnings results for the
fourth quarter ended December 31, 2005, and full-year 2005.
The Company reported net sales of $790 million in the fourth
quarter of 2005, an increase of 29% compared to $611 million in the
fourth quarter of 2004. Unfavorable foreign currency translation
comparisons decreased fourth quarter sales by about $13 million.
Net sales for 2005 were $2.91... |
| | | 01/19/06 | CORRECTED: St. Jude Medical Announces 4th Quarter 2005 Earnings Conference Call|
MINNEAPOLIS--(BUSINESS WIRE)--Jan. 19, 2006--
CHANGED TIME FOR CONFERENCE CALL
St. Jude Medical, Inc. (NYSE:STJ) will hold its quarterly
conference call to discuss the 4th quarter/year-end 2005 earnings
results on Wednesday, January 25, 2006, at 8:30 a.m. Eastern time
(7:30 a.m. Central Time). The news release will be issued at 7:30 a.m.
Eastern time (6:30 a.m. Central time).
This call is being webcast by CCBN and can be accessed at STJ's
web site a... |
| | | 01/13/06 | St. Jude Medical Announces 4th Quarter 2005 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--Jan. 13, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will hold its quarterly conference call to discuss the
4th quarter/year-end 2005 earnings results on Wednesday, January 25,
2006, at 9:00 a.m. Eastern time (8 a.m. Central Time). The news
release will be issued at 8:00 a.m. Eastern time (7:00 a.m. Central
time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CC... |
| | | 01/12/06 | St. Jude Medical to Highlight Broad Portfolio of Innovative Medical Technologies at Boston Atrial Fibrillation Symposium| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 12, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will demonstrate its broad range of cardiac care
technologies--including advanced cardiac visualization and navigation
technology, a surgical cardiac ablation system, and a full line of
catheter-based diagnostic and therapeutic products--at the Boston
Atrial Fibrillation Symposium, January 13 - 14, 2006.
St. Jude Medical supports this important clinical meeting annually
in order to advance the stu... |
| | | 01/10/06 | St. Jude Medical Announces Publication of OPTIC Clinical Study Results in JAMA; Study May Hold the Key to Reducing Shocks in ICD Patients| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 10, 2006--St. Jude Medical,
Inc. (NYSE:STJ) today announced publication of the OPTIC (Optimal
Pharmacological Therapy in Implantable Cardioverter Defibrillator
Patients) clinical study results in the January 11 edition of The
Journal of the American Medical Association (JAMA). The study,
sponsored by St. Jude Medical, shows that patients with an ICD
(implantable cardioverter defibrillator) reduced their chances of
receiving any shock to 10.3% per... |
| | | 01/05/06 | St. Jude Medical Named One of Country's ''Best Managed Companies'' By Forbes| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 5, 2006--St. Jude Medical,
Inc. (NYSE:STJ) announced today that Forbes magazine has named it as
one of America's best managed companies in 2005. "We are very pleased
with this recognition," said Daniel J. Starks, Chairman, President and
Chief Executive Officer of St. Jude Medical, Inc. "This honor belongs
to St. Jude Medical's 10,000-plus employees worldwide who are
committed to the highest quality standards as we strive to bring
outstanding medi... |
| | | 01/04/06 | St. Jude Medical to Present at the 24th Annual JP Morgan Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 4, 2006--St. Jude Medical,
Inc. (NYSE:STJ) will present at the 24th Annual JP Morgan Healthcare
Conference on January 10, 2006, in San Francisco. Dan Starks,
Chairman, President and Chief Executive Officer, will address the
conference at 4:30 p.m. PT. The presentation will be webcast live at
www.sjm.com.
St. Jude Medical is dedicated to making life better for cardiac,
neurological and chronic pain patients worldwide through excellence in
m... |
| | | 01/03/06 | St. Jude Medical Completes Acquisition of Savacor| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 3, 2006--St. Jude Medical,
Inc. (NYSE:STJ) announced today that it has completed the acquisition
of privately held Savacor, Inc.
The acquisition complements the development efforts already
underway at St. Jude Medical in managing congestive heart failure in
patients. Savacor has heart failure diagnostic and therapy guidance
products and technologies under development and in clinical
evaluation, including a small implantable sensor device in... |
| | | 12/06/05 | St. Jude Medical Announces Pricing of Convertible Debt Offering| ST. PAUL, Minn., Dec 06, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) announced today the
pricing of $600 million principal amount of its 2.8% convertible
senior debentures due 2035. In addition, the Company granted the
underwriter an option to purchase up to an additional $60 million
principal amount of the debentures.
The Company intends to repay commercial paper issued to fund its
previously-announced acquisition of Advanced Neuromodulation Systems,
Inc. The closing of the... |
| | | 12/05/05 | St. Jude Medical Announces Convertible Debt Offering| ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 5, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today its intention to offer $600 million in
aggregate principal amount of Convertible Senior Debentures due 2035.
The Company also intends to grant the underwriter an option to
purchase up to an additional $60 million principal amount of the
debentures.
The Company intends to use the net proceeds of the offering to
repay commercial paper issued to fund its previously announced
acquisiti... |
| | | 12/01/05 | St. Jude Medical Announces FDA Approval and Market Launch of New Cardiac Ablation Generator and Therapy(TM) Catheters| ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 1, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval and market release of the IBI-1500T6 Cardiac Ablation
Generator and Therapy(TM) electrophysiology (EP) catheters, expanding
the Company's therapeutic EP portfolio with a new high-power,
state-of-the-art ablation system.
"The introduction of the IBI-1500T6 radiofrequency (RF) generator
and Therapy Dual 8(TM) family of ablation catheter... |
| | | 12/01/05 | St. Jude Medical Announces Agreement to Acquire Savacor, Inc.; Transaction Adds Savacor Heart Failure Sensor Technology Program to Cardiac Rhythm Management Business| ST. PAUL, Minn.--(BUSINESS WIRE)--Dec. 1, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today that it has signed a definitive
agreement to acquire privately held Savacor, Inc.
Based in Los Angeles, California, Savacor has heart failure
diagnostic and therapy guidance products and technologies under
development and in clinical evaluation. The company currently has a
small implantable sensor device in clinical trials both in the United
States and internationally that measures ... |
| | | 11/29/05 | PAVE Study Results to be Published in the Journal of Cardiovascular Electrophysiology; Study Shows That Biventricular Pacing Benefits Non-Heart Failure Patients| ST. PAUL, Minn., Nov 29, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today announced that
results of the PAVE (Post AV Nodal Ablation Evaluation) study will be
published in the Journal of Cardiovascular Electrophysiology in
December 2005. PAVE is the first large-scale study to show the
benefits of biventricular pacing in non-heart failure patients. It
evaluated biventricular pacing versus right ventricular pacing in
patients who had AV nodal ablation (ablate-and-pace) therapy... |
| | | 11/28/05 | St. Jude Medical Completes Tender Offer for Advanced Neuromodulation Systems; Advanced Neuromodulation Systems Shareholders Tender More Than 90 Percent of Outstanding Shares| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 28, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today the successful completion of its cash
tender offer for all of the outstanding shares of Advanced
Neuromodulation Systems, Inc. (NASDAQ:ANSI).
The subsequent offering period of St. Jude Medical's tender offer
to purchase all of the outstanding shares of ANS expired at 5:00 p.m.,
Eastern Time, on Monday, November 28, 2005. Including those shares
tendered during the initial offering p... |
| | | 11/28/05 | St. Jude Medical to Participate in Merrill Lynch Med-Tech Fundamentals Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 28, 2005--St. Jude Medical,
Inc. (NYSE:STJ) will participate in the Merrill Lynch Med-Tech
Fundamentals Conference on December 1, 2005, in New York City. Paul
Buckman, President, Cardiology Division, will participate in a panel
discussion on Interventional Cardiology at the conference at 10:30
a.m. ET. The panel discussion will be webcast live at www.sjm.com.
St. Jude Medical, Inc. (www.sjm.com) is dedicated to the design,
manufacture and d... |
| | | 11/28/05 | St. Jude Medical to Present at Lazard Capital Markets Life Sciences Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 28, 2005--St. Jude Medical,
Inc. (NYSE:STJ) will present at the Lazard Capital Markets Life
Sciences Conference on November 30, 2005, in New York City. John
Heinmiller, Executive Vice President and Chief Financial Officer, will
address the conference at 11:30 a.m. ET. The presentation will be
webcast live at www.sjm.com.
St. Jude Medical, Inc. (www.sjm.com) is dedicated to the design,
manufacture and distribution of innovative medical devic... |
| | | 11/21/05 | St. Jude Medical Extends Subsequent Offering Period By Five Business Days| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 21, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today that the previously announced
subsequent offering period of its tender offer for all outstanding
shares of common stock of Advanced Neuromodulation Systems, Inc.
(NASDAQ:ANSI) has been extended and will now expire at 5:00 p.m.
Eastern Time on Monday, November 28, 2005. The subsequent offering
period was previously scheduled to expire at 12:00 midnight, Eastern
Time, on Friday, November 1... |
| | | 11/17/05 | First Patients Enrolled in St. Jude Medical's Study Looking at AF Suppression Pacing in Heart Failure Patients| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 17, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced that patient enrollment has begun in
the Atrial Fibrillation Suppression Pacing in Cardiac
Resynchronization Therapy Devices (CRT-D) clinical study. The study
evaluates the Company's proprietary AF Suppression(TM) algorithm,
clinically proven to suppress episodes of atrial fibrillation (AF),
and how it impacts the effectiveness of cardiac resynchronization
therapy in heart failure patien... |
| | | 11/16/05 | St. Jude Medical Acquires Approximately 89% Of Advanced Neuromodulation Systems; Announces Subsequent Offering Period| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 16, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today that the tender offer for all of the
outstanding shares of common stock of Advanced Neuromodulation
Systems, Inc. (NASDAQ:ANSI) expired at midnight, Eastern Time,
Tuesday, November 15, 2005. St. Jude Medical has accepted for purchase
and payment all of the shares that were validly tendered as of the
expiration of the offer. The preliminary results of the offer show
that approximately 15,... |
| | | 11/11/05 | St. Jude Medical Obtains Foreign Antitrust Clearance to Acquire Advanced Neuromodulation Systems| ST. PAUL, Minn.--(BUSINESS WIRE)--Nov. 11, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today that the German Federal Cartel Office
confirmed that the acquisition of Advanced Neuromodulation Systems,
Inc. (NASDAQ:ANSI) by St. Jude Medical may be completed. This
approval, together with the previously announced expiration of the
waiting period under the Hart-Scott-Rodino Antitrust Improvements Act
of 1976, satisfies the antitrust approval condition set forth in the
parties' merger ... |
| | | 11/07/05 | St. Jude Medical Named Medical Device Manufacturer of the Year| ST. PAUL, Minn., Nov 07, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) has been named a
Medical Device Manufacturer of the Year by Medical Device and
Diagnostic Industry (MD&DI) magazine. This year the magazine selected
a large public company, a small public company, and a small private
company to receive its annual award.
In naming St. Jude Medical, the publication states, "The company
embodies multiple strengths: good product development, support for
innovation, straight... |
| | | 11/04/05 | St. Jude Medical Obtains HSR Clearance To Acquire Advanced Neuromodulation Systems| ST. PAUL, Minn., Nov 04, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) announced today that
the waiting period under the Hart-Scott-Rodino Antitrust Improvements
Act of 1976 with respect to St. Jude Medical's acquisition of Advanced
Neuromodulation Systems, Inc. (NASDAQ:ANSI) has expired.
On October 18, 2005, St. Jude Medical commenced an all-cash tender
offer for all of the outstanding shares of ANS common stock for $61.25
per ANS share. The tender offer is being made pursuant... |
| | | 10/27/05 | St. Jude Medical Announces European Approval and First Global Implant of New Pacemaker Family| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 27, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced that it has received European CE Mark
approval for the Victory(R) pacemaker family, which allows for sale of
St. Jude Medical's newest pacemaker family in European Union (EU)
countries.
The pacemakers offer an important combination of features,
including optimized settings to save time at implant, VIP(TM)
(Ventricular Intrinsic Preference) technology to minimize ventricular
pacing... |
| | | 10/19/05 | Clinical Trial Demonstrates Device Is Effective in Treating Condition Associated with 200,000 Strokes Annually; New Device from St. Jude Medical Closes Heart Defect, Preventing Unfiltered Blood from Entering Circulation| WASHINGTON--(BUSINESS WIRE)--Oct. 19, 2005--Data from a clinical
trial show that a new device from St. Jude Medical, Inc., (NYSE:STJ)
is effective in treating a common condition associated with more than
200,000 strokes worldwide each year. The PFO (patent foramen ovale)
CLOSE UP (Closure Using Premere(TM)) Trial results were presented this
week at the Cardiovascular Research Foundation's Seventeenth Annual
Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium
by Princi... |
| | | 10/18/05 | St. Jude Medical Commences Tender Offer for Advanced Neuromodulation Systems| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 18, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today that it has commenced a tender offer
for all the outstanding shares of Advanced Neuromodulation Systems,
Inc. (NASDAQ:ANSI) common stock for $61.25 per ANS share in cash.
The tender offer is being made pursuant to the definitive merger
agreement unanimously approved by the Boards of Directors of both
companies and announced on October 16, 2005. The ANS Board of
Directors has recomm... |
| | | 10/18/05 | Clinical Trial Demonstrates Positive Results for St. Jude Medical Device Treating Coronary Bypass Graft Blockages| WASHINGTON, Oct 18, 2005 (BUSINESS WIRE) -- Data from a key clinical trial show that a new embolic
protection device from St. Jude Medical, Inc. (NYSE:STJ) has
demonstrated positive results for treating patients with saphenous
vein coronary bypass grafts. The trial results were presented today
during a Late Breaking Clinical session at the Cardiovascular Research
Foundation's Seventeenth Annual Transcatheter Cardiovascular
Therapeutics (TCT) scientific symposium in Washington, D.C.
The Pr... |
| | | 10/17/05 | St. Jude Medical Reports Third Quarter Sales and Earnings| ST. PAUL, Minn., Oct 17, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today reported results
for the third quarter ended September 30, 2005. The Company reported
net sales of $738 million, an increase of 28% compared to the $578
million reported in the third quarter of 2004. Favorable currency
translation comparisons increased third quarter sales by about $5
million. Net sales for the first nine months of 2005 were $2,125
million, an increase of $442 million or 26% over the $1... |
| | | 10/16/05 | St. Jude Medical and Advanced Neuromodulation Systems Announce Definitive Agreement; Combination Brings St. Jude Medical Complementary Technology Platform in Rapidly-Growing and Underpenetrated Neuromodulation Market| ST. PAUL, Minn. & PLANO, Texas--(BUSINESS WIRE)--Oct. 16,
2005--St. Jude Medical, Inc. (NYSE:STJ) and Advanced Neuromodulation
Systems, Inc. (NASDAQ:ANSI):
-- Conference Call and Webcast for Investors and Analysts
Scheduled for Tomorrow at 7:00 a.m. Central Time (8:00 a.m.
Eastern Time)
-- St. Jude Medical Third Quarter 2005 Earnings Results to be
Issued Tomorrow
St. Jude Medical, Inc. (NYSE:STJ) and Advanced Neuromodulation
Systems,... |
| | | 10/14/05 | St. Jude Medical Announces U.S. Launch of New Technology for Placing Guidewires in Coronary Vessels; Venture(TM) Wire Control Catheter Gives Physicians Greater Agility for Turns Up to 90-Degrees, More Control to Penetrate Challenging Lesions| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 14, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced the U.S. launch of an advanced
catheter for placing guidewires during catheterization procedures. The
Venture(TM) Wire Control Catheter was designed to give cardiologists
more control and support as they steer guidewires during
interventional cardiology procedures such as stenting and angioplasty.
The Venture(TM) catheter features a deflectable tip that can bend
up to 90 degrees, all... |
| | | 10/07/05 | St. Jude Medical Discovers Cosmic Radiation Can Affect Memory Chip in Limited Number of Older Generation ICDs| ST. PAUL, Minn.--(BUSINESS WIRE)--Oct. 7, 2005--St. Jude Medical
Inc. (NYSE:STJ) announced today that it has discovered that background
levels of atmospheric ionizing cosmic radiation, more commonly known
as cosmic rays, can affect a limited number of its older generation
implantable cardioverter defibrillator (ICD) products.
Although the incidence rate is low, and there have been no serious
patient injuries or deaths reported to St. Jude Medical attributable
to this anomaly, th... |
| | | 10/04/05 | St. Jude Medical Introduces Ultra-Thin ICD Lead Family to Japanese Market| ST. PAUL, Minn. & TOKYO--(BUSINESS WIRE)--Oct. 4, 2005--St. Jude
Medical, Inc. (NYSE:STJ) today announced regulatory and reimbursement
approvals from the Ministry of Health, Labor and Welfare in Japan for
the Riata(TM) family of implantable cardioverter defibrillator (ICD)
leads. The highly advanced leads, with diameters as small as 6.7
French, rank among the world's thinnest. They are the first St. Jude
Medical(R) high-voltage leads available in Japan.
"Riata leads provide ... |
| | | 09/28/05 | St. Jude Medical Announces 3rd Quarter 2005 Earnings Conference Call| MINNEAPOLIS--(BUSINESS WIRE)--Sept. 28, 2005--St. Jude Medical,
Inc. (NYSE:STJ) will hold its quarterly conference call to discuss the
3rd quarter 2005 earnings results on Wednesday, October 19, 2005, at
9:00 a.m. Eastern time (8 a.m. Central Time). The news release will be
issued at 8:00 a.m. Eastern time (7:00 a.m. Central time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Inve... |
| | | 09/28/05 | St. Jude Medical Announces Launch of EnSite(R) System 5.1 Software and EnSite Verismo(TM) Segmentation Tool; New Capabilities Enhance Speed and Flexibility of Visualization and Navigation During Electrophysiology Procedures| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 28, 2005--St. Jude
Medical, Inc. (NYSE:STJ) today announced the launch of the EnSite(R)
System Version 5.1 Software and the EnSite Verismo(TM) Segmentation
Tool for use during electrophysiology (EP) procedures. The EnSite(R)
System, a computer-based system designed to facilitate procedures to
treat irregular heartbeats, was included in St. Jude Medical's
acquisition of Endocardial Solutions, Inc. (ESI) in January 2005.
"The introduction of... |
| | | 09/23/05 | St. Jude Medical to Highlight Broad Portfolio of Innovative Medical Technology at European Cardiothoracic Surgeons' Meeting; Company Will Launch Epicor Cardiac Ablation System in European Market| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 23, 2005--St. Jude
Medical, Inc. (NYSE:STJ) will demonstrate its broad range of cardiac
surgery products--including new valve replacement and repair products
and advanced beating-heart cardiac tissue ablation technology--at the
upcoming European Association of Cardiothoracic Surgeons Meeting
(EACTS), September 25-28, in Barcelona, Spain.
St. Jude Medical will begin the European launch of its Epicor(TM)
Cardiac Ablation System at EACTS. Thi... |
| | | 09/19/05 | St. Jude Medical to Present at Banc of America 35th Annual Investment Conference| ST. PAUL, Minn., Sep 19, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will present at the
Banc of America 35th Annual Investment Conference on September 21,
2005, in San Francisco, California. John Heinmiller, Executive Vice
President and Chief Financial Officer, will address the conference at
9:00 a.m. PT. The presentation will be webcast live @www.sjm.com.
St. Jude Medical, Inc. (www.sjm.com) is dedicated to the design,
manufacture and distribution of innovative medical devi... |
| | | 09/13/05 | Enrollment Completed in St. Jude Medical's Study of Microvolt T-Wave Alternans to Identify People at Highest Risk for Sudden Cardiac Death| ST. PAUL, Minn., CLEVELAND, Ohio & BEDFORD, Mass.--(BUSINESS
WIRE)--Sept. 13, 2005--St. Jude Medical, Inc. (NYSE:STJ), MetroHealth
Medical Center and Cambridge Heart, Inc. (OTCBB:CAMH) today announced
completion of patient enrollment in the Alternans Before Cardioverter
Defibrillator (ABCD) clinical study. The study compares the predictive
value of Cambridge Heart's noninvasive Microvolt T-Wave Alternans
Test(TM) with standard, invasive electrophysiology tests in
identifying patients ... |
| | | 09/12/05 | St. Jude Medical Announces Publication of Results for Epicor(TM) Cardiac Ablation System Multi-Center Clinical Trial| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 12, 2005--St. Jude
Medical, Inc. (NYSE:STJ) announced today that the results of a
multi-center clinical study of its High Intensity Focused Ultrasound
(HIFU) cardiac tissue ablation device will be published in the
September 2005 issue of the Journal of Thoracic and Cardiovascular
Surgery (JTCVS).
Using a proprietary approach, the Epicor(TM) technology allows an
ablation device to be placed on the outside of a beating heart and
deliver high in... |
| | | 09/07/05 | St. Jude Medical Pledges $1 Million to Help Rebuild Healthcare Infrastructure in Gulf Coast Region| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 7, 2005--St. Jude Medical
Inc. (NYSE:STJ) announced today that it has pledged $1 million to help
rebuild the healthcare infrastructure in the Gulf Coast region.
"One of the most critical needs in the recovery will be to restore
normal healthcare along the Gulf Coast," said Dan Starks, Chairman,
President and Chief Executive Officer of St. Jude Medical. "We will
work closely with local hospitals and healthcare facilities to target
private secto... |
| | | 09/07/05 | St. Jude Medical to Present at Bear Stearns 18th Annual Healthcare Conference| ST. PAUL, Minn.--(BUSINESS WIRE)--Sept. 7, 2005--St. Jude Medical,
Inc. will present at the Bear Stearns 18th Annual Healthcare
Conference on September 12, 2005, in New York City. John Heinmiller,
Executive Vice President and Chief Financial Officer, will address the
conference at 9:30 a.m. ET. The presentation will be webcast live at
www.sjm.com.
St. Jude Medical, Inc. (www.sjm.com) is dedicated to the design,
manufacture and distribution of innovative medical devices of the
highe... |
| | | 09/01/05 | St. Jude Medical Receives Approvals to Bring State-of-the-Art ICD Technology to Japan; New Releases Signal Company's First Entry into Japanese High-Voltage Market| ST. PAUL, Minn. & TOKYO, Japan--(BUSINESS WIRE)--Sept. 1,
2005--St. Jude Medical, Inc. (NYSE:STJ) today announced regulatory and
reimbursement approvals from the Ministry of Health, Labor and Welfare
in Japan for the Epic(TM)+ and Atlas(R)+ implantable cardioverter
defibrillator (ICD) product families. The devices are the first St.
Jude Medical(R) ICDs available in Japan.
"We are pleased to introduce the premiere Epic+ and Atlas+ ICD
families to Japan," said Paul Bond, President... |
| | | 08/24/05 | St. Jude Medical Announces IDE Approval to begin ESCAPE Migraine Study| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 24, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today that it has received conditional
approval from the U.S. Food and Drug Administration (FDA) of an
Investigational Device Exemption (IDE) to begin enrollment in the
ESCAPE (Effect of Septal Closure of Atrial PFO on Events of Migraine
with Premere(TM)) migraine trial.
St. Jude Medical believes it is the first company to receive FDA
conditional approval to study the potential connection be... |
| | | 08/23/05 | St. Jude Medical to Study Benefits of Cardiac Resynchronization Therapy in Heart Failure Patients with Mechanical Dyssynchrony| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 23, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced first patient enrollment in the
Resynchronization Therapy In Normal QRS (RETHINQ) clinical trial, an
important study that may further identify heart failure patients who
can benefit from cardiac resynchronization therapy (CRT).
The RETHINQ study is designed to evaluate the safety and efficacy
of cardiac resynchronization therapy in patients with advanced heart
failure (NYHA Class III),... |
| | | 08/18/05 | St. Jude Medical Announces First U.S. Implant of SJM Biocor(R) Stented Tissue Valve| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 18, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today the first implant of the SJM Biocor(R)
stented tissue valve in the United States. The Company announced U.S.
Food and Drug Administration (FDA) approval of the SJM Biocor(R) valve
- its first stented tissue valve in the U.S. market - on August 8,
2005.
The first U.S. implant of the device was performed on August 12,
2005, in a 72-year-old male patient by James R. Taylor, M.D., a
cardi... |
| | | 08/08/05 | St. Jude Medical Receives FDA Approval For Biocor(R) Stented Tissue Valve| ST. PAUL, Minn., Aug 08, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) announced today it has
received U.S. Food and Drug Administration (FDA) approval for the SJM
Biocor(R) and Biocor(R) Supra family of stented tissue valves, the
Company's first stented tissue valves in the U.S. market.
The approval will allow St. Jude Medical, long known for its
leadership in mechanical heart valves, to bring its expertise to the
U.S. stented tissue valve segment, which currently represen... |
| | | 08/05/05 | Company Profile for St. Jude Medical, Inc.| --(BUSINESS WIRE)--St. Jude Medical, Inc. (www.sjm.com) is
dedicated to the design, manufacture and distribution of innovative
medical devices of the highest quality, offering physicians, patients
and payers outstanding clinical performance and demonstrated economic
value.
Company: St. Jude Medical, Inc.
Headquarters Address: One Lillehei Plaza
St. Paul, Minnesota 55117
Main Telephone: 651.483.2000
Ticker: ... |
| | | 08/04/05 | St. Jude Medical Elects John W. Brown to Board of Directors| ST. PAUL, Minn.--(BUSINESS WIRE)--Aug. 4, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced the election of John W. Brown to a
newly-created position on its Board of Directors, effective
immediately. Mr. Brown is Chairman of the Board of Stryker Corp., a
worldwide leader in orthopaedic medical devices, and served as Chief
Executive Officer of Stryker from 1977 to January 1, 2005.
"We are extremely pleased to have John Brown join the St. Jude
Medical Board of Directors," said D... |
| | | 07/28/05 | St. Jude Medical Announces Exclusive European Co-Promotion Alliance with HemoSense, Inc. to Assist Mechanical Heart Valve Patients with Anticoagulation Therapy Management| ST. PAUL, Minn.--(BUSINESS WIRE)--July 28, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced an exclusive agreement in most
European countries with HemoSense, Inc. (AMEX:HEM) to increase
awareness and access to self-testing and monitoring the effectiveness
of anticoagulation medication or Coumadin(R) (warfarin) for mechanical
heart valve patients.
Mechanical heart valve patients take blood-thinning medication to
minimize the risk of thrombolic events and, as a result, regularl... |
| | | 07/20/05 | St. Jude Medical Reports Second Quarter Sales and Earnings| ST. PAUL, Minn., Jul 20, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) today reported results
for the second quarter ended June 30, 2005. The Company reported net
sales of $724 million, an increase of 30% compared to the $557 million
reported in the second quarter of 2004. Favorable foreign currency
translation comparisons increased second quarter sales by about $12
million.
Reported net earnings for the second quarter of 2005 were $101
million or $.27 per diluted share, c... |
| | | 07/07/05 | St. Jude Medical Announces FDA Approval of New Housecall Plus(TM) System Software Designed to Advance Remote Patient Monitoring| ST. PAUL, Minn.--(BUSINESS WIRE)--July 7, 2005--In an effort to
provide important new communications benefits to medical professionals
who remotely monitor implantable cardioverter defibrillator (ICD)
patients, St. Jude Medical, Inc. (NYSE:STJ) announced today it has
received U.S. Food and Drug Administration (FDA) approval of its
version 2.1 software upgrade for the Housecall Plus(TM) remote patient
monitoring system.
This upgrade enables medical professionals to create electronic
... |
| | | 06/24/05 | St. Jude Medical Announces 2nd Quarter 2005 Earnings Conference Call| MINNEAPOLIS, Jun 24, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will hold its
quarterly conference call to discuss the 2nd quarter 2005 earnings
results on Wednesday, July 20, 2005, at 9:00 a.m. Eastern time (8 a.m.
Central Time). The news release will be issued at 8:00 a.m. Eastern
time (7:00 a.m. Central time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distri... |
| | | 06/20/05 | St. Jude Medical Announces ICD Software Upgrade Notification to Physician Customers| ST. PAUL, Minn.--(BUSINESS WIRE)--June 20, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today that it has notified physicians that
certain of its implantable cardioverter defibrillators (ICDs) are in
need of a non-invasive, 45-second software upgrade to correct two
anomalies found during routine product evaluation.
The anomalies do not pose a significant risk to patients and the
Company has not received any reports of patient adverse events or
clinical complications as a result... |
| | | 05/23/05 | St. Jude Medical Announces European Launch of Three Cardiology Products at EuroPCR 2005 Meeting in Paris| ST. PAUL, Minn.--(BUSINESS WIRE)--May 23, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced the European launch of three new
advanced cardiology products at the EuroPCR 2005 meeting, May 24-27,
in Paris, France. EuroPCR is one of Europe's largest medical education
meetings focused on the interventional cardiology and radiology
markets.
The products - the Premere(TM) PFO closure device, the Proxis(TM)
embolic protection device, and the Venture(TM) wire control catheter -
were ... |
| | | 05/19/05 | FDA Approves Heart Failure Indication for St. Jude Medical's Frontier(TM) II System|
ST. PAUL, MN, May 19, 2005 -- St. Jude Medical, Inc. (NYSE: STJ) today announced U.S. Food and Drug Administration (FDA) approval of the Frontier ™ II system for cardiac resynchronization therapy pacing (CRT-P) to reduce the symptoms of moderate to severe heart failure (NYHA Class III or IV and EF is less than or equal to 35% and prolonged QRS) who remain symptomatic despite optimal drug therapy.
The Frontier™II system is currently the only device family approved in the United States ... |
| | | 05/11/05 | St. Jude Medical Announces Results of Shareholders' Vote at Annual Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--May 11, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced at the annual meeting of shareholders today
that Richard R. Devenuti, Stuart M. Essig, Thomas H. Garrett III, and
Wendy L. Yarno were re-elected to the Company's Board of Directors for
three-year terms.
In addition, shareholders ratified the appointment of Ernst and
Young LLP as the Company's Independent Registered Public Accountants
and rejected a shareholder proposal that would have limited... |
| | | 05/04/05 | St. Jude Medical Announces FDA Approval and Market Launch of the IsoFlex P Polyurethane Pacing Lead| ST. PAUL, Minn.--(BUSINESS WIRE)--May 4, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration
(FDA) approval and market release of the IsoFlex(R) P (polyurethane)
bipolar, endocardial pacing lead. The lead, which is built on the
proven IsoFlex(R) passive-fixation pacing lead platform, offers 55D
polyurethane outer insulation, steroid-elution and advanced features
designed to improve performance and device longevity.
"The IsoFlex P lead demonstrat... |
| | | 05/04/05 | St. Jude Medical to Present Innovative Technologies and Important Clinical Updates at Heart Rhythm 2005| ST. PAUL, Minn.--(BUSINESS WIRE)--May 4, 2005--St. Jude Medical
Inc. (NYSE:STJ) will showcase its most advanced cardiac care products
and present the latest data from clinical studies at Heart Rhythm
2005, the 26th Annual Scientific Sessions of the Heart Rhythm Society
(HRS), to be held May 4th - 7th in New Orleans, Louisiana.
"Heart Rhythm 2005 brings together the world's leading
electrophysiologists and cardiologists to discuss breakthrough cardiac
technologies and review the late... |
| | | 04/20/05 | St. Jude Medical Reports First Quarter Sales and Earnings| ST. PAUL, Minn.--(BUSINESS WIRE)--April 20, 2005--St. Jude
Medical, Inc. (NYSE:STJ) today reported results for the first quarter
ended March 31, 2005. The Company reported net sales of $664 million,
an increase of 21% compared to the $549 million reported in the first
quarter of 2004. Favorable foreign currency translation comparisons
increased first quarter sales by about $15 million.
Reported net earnings for the first quarter of 2005 were $119
million or $.32 per diluted share, c... |
| | | 04/18/05 | St. Jude Medical Announces FDA Approval and U.S. Launch of Bipolar CRT Lead| ST. PAUL, Minn., Apr 18, 2005 (BUSINESS WIRE) -- St. Jude Medical Inc. (NYSE:STJ) today announced U.S.
Food and Drug Administration (FDA) approval of the Company's
QuickSite(R) 1056T bipolar lead. The lead is used in CRT (cardiac
resynchronization therapy) applications for heart failure patients and
will be launched in the U.S. market in advance of the Heart Rhythm
2005 Scientific Sessions that begins May 4th.
"The bipolar design and excellent stability of the QuickSite 1056T
lead all... |
| | | 04/14/05 | St. Jude Medical Upgrades All Epic HF and Atlas+ HF Devices with V-V Timing Programmability| ST. PAUL, Minn.--(BUSINESS WIRE)--April 14, 2005--In an effort to
provide important, cutting-edge technologies to even more heart
failure patients, St. Jude Medical, Inc. (NYSE:STJ) announced today
that it has received U.S. Food and Drug Administration (FDA) approval
to activate V-V (ventricle to ventricle) timing in all models of its
Epic(TM) HF and Atlas(R)+ HF CRT-Ds (cardiac resynchronization therapy
defibrillators). Thousands of patients implanted with these devices
now have the impo... |
| | | 04/11/05 | St. Jude Medical to Profile the Epicor Cardiac Ablation System at American Association of Thoracic Surgeons Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--April 11, 2005--St. Jude
Medical, Inc. (NYSE:STJ) today announced it is profiling the
Epicor(TM) Cardiac Ablation System, featuring High Intensity Focused
Ultrasound (HIFU) technology, at the American Association of Thoracic
Surgeons (AATS) meeting April 10 - 12 in San Francisco, California.
The Company is also showcasing its broad range of mechanical and
tissue heart valves, repair products, and other cardiac surgery
offerings at Booth #1519.
The ... |
| | | 04/06/05 | St. Jude Medical Completes Acquisition of Velocimed| ST. PAUL, Minn., Apr 06, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) announced today it has
completed the acquisition of the business of Velocimed, LLC
(Velocimed), a privately owned company that develops, manufactures,
and markets specialty interventional cardiology devices. The
transaction was announced on February 15, 2005. The Company is paying
$74 million in cash with further contingent payments due upon
achievement of regulatory and other milestones, the earliest of whi... |
| | | 03/29/05 | St. Jude Medical Announces 1st Quarter 2005 Earnings Conference Call| MINNEAPOLIS, Mar 29, 2005 (BUSINESS WIRE) -- St. Jude Medical, Inc. (NYSE:STJ) will hold its
quarterly conference call to discuss the 1st quarter 2005 earnings
results on Wednesday, April 20, 2005, at 9:00 a.m. Eastern time (8
a.m. Central Time). The news release will be issued at 8:00 a.m.
Eastern time (7:00 a.m. Central time).
This call is being webcast by CCBN and can be accessed at STJ's
web site at www.sjm.com.
The webcast is also being distributed over CCBN's Investor
Distr... |
| | | 03/22/05 | Twenty-Five Year Retrospective Study with St. Jude Medical Mechanical Heart Valve Published in Annals of Thoracic Surgery| ST. PAUL, Minn., Mar 22, 2005 (BUSINESS WIRE) -- The St. Jude Medical(R) mechanical heart valve has
proven to be an effective and durable valve with low complication
rates, according to a 25-year retrospective study published in the
March issue of the Annals of Thoracic Surgery. The study, conducted by
Minnesota-based Cardiac Surgical Associates, is one of the longest,
largest and most comprehensive studies on a bileaflet prosthetic heart
valve.
The study analyzed 4,480 patients from ... |
| | | 03/14/05 | New PSA Wand from St. Jude Medical Integrates Testing, Programming and Interrogation of Implantable Cardiac Devices| ST. PAUL, Minn.--(BUSINESS WIRE)--March 14, 2005--St. Jude
Medical, Inc. (NYSE:STJ) announced today the global launch of its
first integrated pacing system analyzer (PSA) wand. The wand, which
attaches to St. Jude Medical programmers, enables clinicians to
conduct implantation testing and performance threshold testing, as
well as programming and interrogation of pacemakers, implantable
cardioverter defibrillators (ICDs) and emerging indications devices
without the need for separate analyz... |
| | | 03/04/05 | St. Jude Medical to Present OPTIC Clinical Study Results at the 2005 ACC Scientific Sessions; New Products Portfolio to be Showcased at Meeting| ST. PAUL, Minn.--(BUSINESS WIRE)--March 4, 2005--St. Jude Medical
Inc. (NYSE:STJ) will announce the findings of a major clinical trial
and present its newest cardiac products at the American College of
Cardiology's Annual Scientific Session 2005 to be held March 6-9 in
Orlando, Florida.
Results of OPTIC (Optimal Pharmacological Therapy in Implantable
Cardioverter Defibrillator Patients), a multi-center, randomized
clinical study designed to evaluate the effectiveness of combining
a... |
| | | 02/24/05 | St. Jude Medical Begins Enrollment in the ASSERT Clinical Study to Evaluate the Relationship Between Atrial High Rate Episodes and Stroke| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 24, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today enrollment of the first patients in
the ASSERT (ASymptomatic AF and Stroke Evaluation in Pacemaker
Patients and the AF Reduction Atrial Pacing Trial) clinical study. The
study will follow 2,500 patients for 3 1/2 years to determine if
pacemaker-detected AHRE (Atrial High Rate Events) predict an increased
risk of stroke in elderly hypertensive patients without previous
atrial fibrillation (AF... |
| | | 02/15/05 | St. Jude Medical Announces Agreement to Acquire Velocimed; Velocimed Products Expand St. Jude Medical's Cardiology Business| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 15, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today it has signed a definitive agreement
to acquire the business of Velocimed, LLC ("Velocimed"), a
privately-owned company located in Maple Grove, Minnesota. Velocimed
develops and manufactures specialty interventional cardiology devices.
Under the terms of the agreement, St. Jude will acquire Velocimed's
business for a cash purchase price of $82.5 million, less an estimated
$8.5 million of cas... |
| | | 02/07/05 | St. Jude Medical Announces the European Market Launch of the QuickSite 1056T Bipolar CRT Lead; World's First Bipolar CRT Lead with Composite Body and ''S'' Tip| ST. PAUL, Minn.--(BUSINESS WIRE)--Feb. 7, 2005--St. Jude Medical,
Inc. (NYSE:STJ) announced today the European market launch of the
QuickSite(R) 1056T bipolar left-heart pacing lead, the world's first
cardiac resynchronization therapy (CRT) lead to combine bipolar pacing
capability with a composite body for superior handling and a unique
S-shaped distal tip for outstanding stability. The lead represents the
next advance in the QuickSite(R) family of left-heart leads.
"We are very pl... |
| | | 01/26/05 | St. Jude Medical Reports 2004 Results| ST. PAUL, Minn.--(BUSINESS WIRE)--Jan. 26, 2005--St. Jude Medical,
Inc. (NYSE:STJ) today reported fourth quarter and full-year 2004 sales
and earnings, led by sales of the Company's implantable cardioverter
defibrillator (ICD) products.
Net sales for the fourth quarter of 2004 were $611 million,
compared to $519 million in the fourth quarter of 2003, an increase of
18%. Favorable foreign currency translation comparisons increased
fourth quarter sales by about $17 million.
Net... |
| |
|
|
|
